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APPLICATION OF ELECTRICAL 
STIMULATION FOR FUNCTIONAL TISSUE 
ENGINEERING IN VITRO AND IN VIVO 
This application claims priority from U.S. Provisional 
Application No. 60/480,214, filed Jun. 20, 2003, the entire 
contents of which are incorporated herein by reference. To the 
extent that the incorporated contents conflict with this appli-
cation, this application shall prevail. 
GOVERNMENT INTERESTS 
The work described herein was partly supported by the 
National Aeronautics and Space Administration (NASA, 
Grant No. NCC8-174). The United States government may 
have certain rights in the invention. 
BACKGROUND OF THE INVENTION 
Cardiovascular diseases are responsible for a preponder-
ance of health problems in the majority of the developed 
countries as well as in many developing countries. Heart 
disease and stroke, the principal components of cardiovascu-
lar disease, are the first and third leading cause of mortality in 
the U.S., accounting for nearly 40% of all deaths (Heart and 
Stroke Statistical Update, American Heart Association 2002). 
Cardiovascular diseases also include congenital heart defects, 
which occur in about 1% of live births (R. F. Gillum, Am. 
Heart J. 1994, 127: 919-927) and are the main cause of mor-
tality in the first year of life (J. L. Hoffman, Pediatr. Cardiol. 
1995, 16: 103-113 and 115-165). When they do not lead to 
death, cardiovascular diseases may alternatively result in sub-
stantial disability and loss of productivity. About 61 million 
Americans (almost one-fourth of the population) live with 
cardiovascular disorders, such as coronary heart disease, con-
genital cardiovascular defects, and congestive heart failure. In 
2001, 298.2 billion dollars were spent in the treatment of 
these clinical conditions, and the economic impact of cardio-
vascular disease on the U.S. health care system is expected to 
grow as the population ages. 
Over the past 30 years, advances in the treatment and 
prevention of cardiac diseases have led to constantly declin-
ing morbidity and mortality rates. Treatments for both con-
genital heart defects and cardiomyopathies have become 
more sophisticated. However, when these treatments fail, 
organ or tissue replacement remains the only other possible 
option. Different surgical procedures may be performed to 
treat heart failure and cardiac deficiency. These procedures 
include transplantation of organs from one individual to 
another, reconstructive surgery, and implantation of mechani-
cal devices such as mechanical heart valves. 
Cardiac transplantation is so common that the primary 
limitation on patient outcome is not the surgical technique, 
but the declining availability of donor organs. In 2000, 2,500 
heart transplants were performed in the U.S. while it was 
estimated thatbetween 20,000 and 40,000 patients could have 
benefited from such a medical operation. To circumvent the 
problem of donor organ scarcity, one can resort to surgical 
reconstruction, whereby damaged or defective tissue at one 
site of the patient is replaced by healthy tissue from another 
part of the patient's body. These autografts include blood 
vessel grafts for heart bypass surgeries. The disadvantages of 
using autografts are their limited durability (E. Braunwald, 
Heart Disease 4th Edition, E. Braunwald (Ed.), W. B. Saun-
ders: Philadelphia, Pa., 1992, pp. 1007-1077) and a loss of 
function at the donor site. In addition, reconstructive surgery 
often involves using the body's tissues for purposes not origi- 
2 
nally intended, which can result in long-term complications. 
Mechanical heart valve prostheses have proved to effectively 
improve patient's quality of life. However, they are also sub-
ject to mechanical failure and rejection, can induce inflam- 
5 mation and/or infection, and require long-term drug interven-
tion to prevent blood-clotting. Furthermore, since these 
mechanical valve substitutes are nonviable, they have no 
potential to grow, to repair or to remodel; therefore their 
durability is limited, especially in growing children (J. E. 
io Mayer Jr., Semin. Thorax Cardiovasc. Surg. 1995, 7: 130-
132). Since currently available treatments (with the exception 
of cardiac transplantation) are only palliative, new drugs and 
procedures for treating cardiovascular diseases, especially 
approaches allowing the recovery of diminished cardiac func- 
15 tion, are highly desirable. 
Tissue engineering is emerging as a significant potential 
alternative or complementary solution. In tissue engineering, 
tissue or organ failure is addressed by implanting natural, 
synthetic, or semi-synthetic tissue and organ mimics that are 
20 fully functional from the start or that grow into the required 
functionality to replace, repair, maintain and/or enhance 
organ/tissue function. Although efforts to generate bioartifi-
cial tissues and organs for human therapies go back at least 
thirty years, such efforts have come closer to clinical success 
25 only in the last ten years. In addition to developing improved 
bioartificial tissue equivalents for therapeutic purposes as 
well as for in vitro research and drug development, tissue 
engineering also aims at providing measures to enhance sur-
vival and integration of engineered grafts following implan- 
30 tation in vivo. 
One of the major strategies adopted for the creation of 
engineered tissues is the in vitro growth of isolated cells on 
three-dimensional templates or scaffolds under conditions 
that coax the cells to develop into a functional tissue. The 
35 scaffolds, which can be fashioned from synthetic polymers or 
from natural materials such as collagen, temporarily provide 
the biomechanical support needed by the cells. As the cells 
grow and differentiate on the scaffold, they produce their own 
extracellular matrix. When implanted, the bioartificial tissue 
40 should become structurally and functionally integrated into 
the body. 
The feasibility of engineered functional cardiac muscle has 
been demonstrated (T. Eschenhagen et al., FASEB J. 1997, 
11: 683-694; L. E. Freed and G. Vunjak-Novakovic, In Vitro 
45 Cell Dev. Biol. 1997,33:381-385; R. Akins et al., Tissue Eng. 
1999, 5: 103-118; N. Bursac et al., Am. J. Physiol. Heart Circ. 
Physiol. 1999, 277: H433-H444; R. L. Carrier et al., Biotech-
nol. Bioeng. 1999, 64: 580-589). Eschenhagen and co-work-
ers (T. Eschenhagen et al., FASEB J. 1997, 11: 683-694) 
50 showed that embryonic chick cardiac myocytes cultured in 
collagen gels displayed characteristic physiological 
responses to physical andpharmacological stimuli; andAkins 
et al. (R. Akins et al., Tissue Eng. 1999, 5: 103-118) demon-
strated that rat ventricular cardiomyocytes cultured on poly- 
55 styrene microcarrier beads in bioreactors formed three-di-
mensional spontaneously contractile aggregates. Cultivation 
of neonatal rat cardiac myocytes on polyglycolic scaffolds in 
bioreactors has been shown to result in contractile three-
dimensional tissues (L. E. Freed and G. Vunjak-Novakovic, 
60 In Vitro Cell Dev. Biol. 1997, 33: 381-385) with ultrastruc-
tural features of cardiac muscle (N. Bursac et al., Am. J. 
Physiol. Heart Circ. Physiol. 1999, 277: H433-H444). These 
studies also provided evidence that variations in initial cell 
density and cultivation conditions affect the structure of the 
65 engineered cardiac tissue produced (R. L. Carrier et al., Bio-
technol. Bioeng. 1999, 64: 580-589; M. Papadaki et al., Am. 
J. Physiol. Heart Circ. Physiol. 2001, 280: H168-H178). 
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One of the major difficulties in engineering a functional 	 is one that contains electrically excitable cells and is subject 
cardiac tissue starting from isolated cells is the heart's com- 	 to electrical stimulation in vivo, such as, for example, cardiac 
plex structure and function at different spatial scales. The 	 muscle tissue, striated skeletal muscle tissue, smooth muscle 
complex structure of the heart stems from the elongation and 
	
tissue, bone, vasculature, or nerve tissue. 
spatial alignment of cardiac myocytes, from the distribution 5 	 Cultivating the cell-seeded construct may include implant- 
of intercellular connections, and from the formation of car- 	 ing the cell-seeded construct in vivo and placing the cell- 
diac muscle fibers and bundles that rotate transmurally inside 	 seeded construct in electrical communication with a source of 
the heart wall. This unique architecture of cardiac tissue 	 biomimetic electrical stimulation. The method may further 
enables an orderly sequence of electrical and mechanical 
	 include cultivating the cell-seeded construct in perfusion. The 
activity and efficient pumping of blood from the heart. Unsur-  io cell-seeded construct may be cultivated in perfusion in the 
prisingly, the intricate arrangement and geometrical order of 	 presence of the biomimetic electrical stimulation. 
different cell types in living cardiac muscle tissue is difficult 
	 In some embodiments, the substrate used in the preparative 
to reproduce in vitro; and standard tissue engineering culture 	 methods is biocompatible. This is particularly important 
of cardiac muscle cells seldom yields tissue of such complex 	 when the three-dimensional tissue-engineered construct pro- 
structure. 	 15 duced is to be implanted in a patient. Depending on the 
Indeed, most tissue engineering techniques used so far 	 intended purpose of the construct, the substrate may be bio- 
have led to cardiac muscle constructs with a number of short- 	 degradable or non-biodegradable; it may comprise a natu- 
comings that limit their usefulness for both in vitro and in vivo 	 rally-occurring polymer, a synthetic polymer, or any combi- 
applications. Most often, unlike native cardiac muscle that 	 nation of naturally-occurring and/or synthetic polymers. The 
consists of fibers with a defined orientation, the cells in engi-  20 substrate may have a dry thickness of at least 1.5 mm. 
neered constructs exhibit random orientation and a poor 	 In certain embodiments, the mammalian cells used in the 
degree of differentiation. Furthermore, the constructs often 	 preparative methods of the invention comprise cells of one 
present a non-uniform spatial cell distribution with, for 	 cell type. In other embodiments, mammalian cells are of at 
example, a good tissue formation at the periphery and a loose 	 least two different cell types. Suitable mammalian cells 
network of disoriented cells at the center of the construct. 25 include neonatal cells, adult or aged cells, progenitor cells, 
Since only a minor fraction of the three-dimensional structure 	 genetically transformed cells, adult stem cells, mesenchymal 
consists of cardiac tissue, its usefulness as a medical implant 	 stem cells, and embryonic stem cells. In still other embodi- 
for replacement therapy is limited. Furthermore, it is gener- 	 ments, the mammalian cells are human cells. 
ally recognized that structural and functional integration of 
	
For example, when the inventive methods of preparation 
engineered grafts remains unsolved. Even if high-fidelity so are applied to produce a three-dimensional tissue-engineered 
engineered tissue equivalents become available, the process 	 cardiac muscle construct, the mammalian cells may be 
of integration will need to be enhanced for the tissue graft to 	 selected from the group consisting of cardiomyocytes, 
survive implantation and remain functional. 	 endocardial cells, cardiac adrenergic cells, cardiac fibro- 
Therefore, a need continues to exist for new strategies that 
	 blasts, vascular endothelial cells, smooth muscle cells, car- 
offer novel and satisfactory platforms for in vitro research and 35 diac progenitor cells, adult stem cells, mesenchymal stem 
the eventual development of compact, thick and functional 	 cells, embryonic stem cells, and combinations of these. In 
transplantable heart muscle. In particular, methods for the 	 certain embodiments, the inventive preparation methods fur- 
production of three-dimensional bioartificial constructs with 
	
ther comprise the step of harvesting mammalian cells from an 
properties resembling those of native cardiac tissue are highly 	 individual and cultivating these cells in vitro before contact- 
desirable, as are methods allowing their enhanced integration 40 ing the substrate. When the construct is intended to be used as 
and functionality in vivo. 	 a medical implant, the mammalian cells may be of autologous 
and/or heterologous origin. 
SUMMARY OF THE INVENTION 
	
In other embodiments, the cultivation of the cell-seeded 
construct is carried out under conditions selected to promote 
The present invention is directed to improved systems for 45 deposition of extracellular matrix components. The cultiva- 
the development of bioartificial tissues in vitro and their inte- 	 tion of the cell-seeded construct may also be carried out under 
gration with host tissues following implantation in vivo. More 	 conditions that promote cell proliferation and/or cell differ- 
specifically, the present invention provides strategies that (a) 	 entiation. Alternatively or additionally, the cultivation may be 
allow the formation of three-dimensional tissue-engineered 	 carried out under conditions and for a time period such that 
constructs having structural and functional characteristics of 50 they allow the formation of a three-dimensional construct 
a native tissue, and that (b) enhance the integration of engi- 	 with a pre-determined thickness. The cultivation conditions 
neered and host tissues following implantation of the con- 	 may also be chosen to stimulate the formation of a three- 
struct in vivo. The invention further provides three-dimen- 	 dimensional construct, wherein the cells are organized on the 
sional tissue-engineered constructs that can be used as 	 substrate with a defined orientation. 
bioartificial tissue equivalents for in vitro research and/or as 55 	 The cell-seeded construct is cultivated in the presence of an 
medical implants for the repair and replacement of deficient 	 electrical stimulation that mimics the electrical stimulation 
or damaged natural structure(s). 	 received by a specific native tissue in vivo. For example, the 
In one aspect, the present invention provides preparation 	 production of a three-dimensional tissue-engineered cardiac 
methods of three-dimensional tissue-engineered constructs. 	 muscle construct using the inventive methods comprises cul- 
More specifically, the inventive methods comprise contacting 60 tivation of the cell-seeded construct in the presence of an 
an appropriate substrate with mammalian cells to form a 	 electrical stimulation that mimics the electrical stimulation 
cell-seeded construct, and cultivating the resulting cell- 	 received by a cardiac muscle tissue in vivo. Furthermore, 
seeded construct in the presence of a biomimetic electrical 	 when the mammalian cells are cardiac progenitor cells and/or 
stimulation. The cultivation is carried out under conditions 	 stem cells, the cardiac-like electrical stimulation is used to 
and for a time period that allow the formation of a three- 65 induce their differentiation into cardiac myocytes. 
dimensional cell structure having structural and functional 
	
The electrical stimulation used to produce a tissue-engi- 
characteristics of a native tissue. Preferably, the native tissue 	 neered construct may alternatively be chosen to mimic the 
US 8,367,410 B2 
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electrical stimulation received by a striated skeletal muscle 
tissue, smooth muscle tissue, bone, vasculature, or nerve tis-
sue in vivo. 
In other embodiments, the inventive methods further com-
prise the step of stimulating the cell-seeded construct 
mechanically and/or chemically. 
In still other embodiments, the inventive preparation meth-
ods further comprise the step of treating the three-dimen-
sional tissue-engineered construct with at least one biologi-
cally active agent. The biologically active agent may be 
selected from the group consisting of growth factors, adhe-
sion factors, soluble extracellular matrix proteins, antibiotics, 
agents that enhance vascularization, agents that enhance cell 
differentiation, agents that enhance tissue differentiation, 
agents that inhibit fibrosis, agents that inhibit tumorigenesis, 
agents that enhance cell proliferation, agents that inhibit cell 
proliferation, agents that inhibit scaffold degradation, agents 
that enhance scaffold degradation, agents that enhance histo-
compatibility, and agents that enhance hemocompatibility. 
Steps of submitting the three-dimensional tissue-engi-
neered construct to further tissue engineering and/or of stor-
ing the three-dimensional tissue-engineered construct after 
preparation by the inventive methods are also intended to be 
within the scope of the present invention. 
In another aspect, the present invention is directed to tis-
sue-engineered constructs comprising mammalian cells orga-
nized on a substrate to provide a three-dimensional cell struc-
ture having structural and functional characteristics of a 
native tissue, wherein the three-dimensional cell structure is 
obtained by contacting the substrate with mammalian cells to 
form a cell-seeded construct, and cultivating the resulting 
cell-seeded construct in the presence of a biomimetic electri-
cal stimulation. Substrates and mammalian cells suitable for 
the production of the inventive three-dimensional tissue con-
structs are as described above. 
In certain embodiments, the inventive constructs have 
structural and functional characteristics of a native tissue that 
contains electrically excitable cells and is subject to electrical 
stimulation in vivo, such as cardiac muscle tissue, striated 
skeletal muscle tissue, smooth muscle tissue, bone, vascula-
ture, or nerve tissue. 
In still other embodiments, the inventive constructs may 
further comprise extracellular matrix components, such as 
fibronectin, collagen type IV, collagen type I, laminin, throm-
bospondin, vibronectin, proteoglycans, hyaluronan, and 
nidogen. Additionally or alternatively, the cells on the sub-
strate may be organized with a defined orientation. In yet 
other embodiments, the inventive three-dimensional tissue-
engineered constructs may further comprise at least one bio-
logically active agent, as listed above. 
In another aspect, the present invention provides methods 
for treating an individual suffering from tissue deficiency, 
damage or loss. These methods include producing a three-
dimensional tissue-engineered construct according to the 
preparation methods described above; implanting the con-
struct into the individual in need thereof, and submitting the 
implanted construct to a biomimetic electrical stimulation. 
The electrical stimulation may enhance integration of the 
implanted construct with host tissue, and/or may increase cell 
survival and/or cell functionality in vivo. The construct to be 
implanted may further comprise at least one biologically 
active agent, and thereby serve as vehicle for delivery of the 
biologically active agent(s) to the individual. The inventive 
methods of treatment are particularly useful when the tissue 
to be replaced or supplemented is one that is subject to elec-
trical stimulation in vivo. The inventive methods may, for 
example, be applied for treating an individual suffering from 
6 
tissue deficiency, damage or loss associated with a congenital 
heart disease or with an acquired heart disease. 
In yet another aspect, the invention provides methods for 
testing three-dimensional tissue-engineered constructs in 
5 vitro. These methods comprise producing a construct accord-
ing to the preparative methods described above, exposing the 
construct to a test factor, and observing a response of the 
construct to the test factor. 
Suitable test factors include, but are not limited to, 
10 
mechanical stimulus, electrical stimulus, temperature, pH, 
gas content, oxygen concentration, inorganic molecules, 
organic molecules, biologically active agents (such as those 
listed above), plant extracts, drugs, and potential therapeutic 
15 candidates. 
In certain embodiments, observing the response of the 
construct to the test factor comprises studying or assessing at 
least one property of the construct. The properties of the 
construct that can be studied or assessed include, for example, 
20 strength, elasticity, durability, conductivity, contractility, tis-
sue organization, cellular organization, cell viability, cell 
morphology, metabolic activity, cell cycle progression, frac-
tion of apoptotic cells, ultrastructural features, electrical sig-
nal propagation, gene expression, and protein expression. 
25 Different methods may be used to observe the response of the 
construct to the test factor. 
Other aspects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
30 detailed description and specific examples, while indicating 
preferred embodiments of the invention, are given by way of 
illustration only. 
BRIEF DESCRIPTION OF THE DRAWING 
35 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawings will be provided by the 
Office upon request and payment of the necessary fee. 
40 FIG. lA is a schematic diagram of an exemplary perfusion 
system for seeding of some constructs according to an 
embodiment of the invention. 
FIG. 1B is a schematic diagram of a perfusion system for 
culturing constructs according to an embodiment of the 
45 invention. 
FIG. 2 is a photograph showing a multi-well simulation 
chamber having two carbon electrodes that are connected to a 
commercial cardiac stimulator via two platinum wire and 
alligator clamps. 
50 	 FIG. 3 is composed of 4 fluorescence microscope images 
of stained cardiac constructs cultivated in the presence and in 
the absence of an electrical stimulation. The alignment of 
myotubes and expression of contractile proteins in engi-
neered cardiac tissue cultivated for 8 days in a standard set-up 
55 are displayed inparts A and B, while parts C and D present the 
same features for a cardiac muscle tissue cultivated in one 
particular series of experiments for a total period of 8 days 
(including 5 days of cultivation in the presence of an electrical 
stimulation). Parts A and C show staining of the contractile 
60 protein cardiac troponin I. Parts B and D show staining of the 
contractile protein sarcomeric a-actin (see Example 2 for a 
description of the experimental conditions used to stain the 
contractile proteins). 
FIG. 4A is a photograph of a set of protein blots for quan- 
65 titative measurement of protein expression in a construct 
produced according to an embodiment of the invention. The 
ratio of alpha MHC to beta MHC is 1.5 after 3 days, 1.4 after 
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four more days in culture without electrical stimulation, and 
1.8 after four more days in culture with electrical stimulation. 
FIG. 4B is a photograph of a set of blots for quantitative 
measurement of gene expression in electrically stimulated 
constructs produced according to an embodiment of the 
invention and non-stimulated constructs. 
FIG. 5 is a series of electron micrographs ofA) native heart 
tissue, B) stimulated construct produced according to an 
embodiment of the invention and C) non-stimulated con-
struct. 
FIG. 6 is a graph showing the change fractional area change 
upon contraction with time for a construct produced accord-
ing to an embodiment of the invention. 
FIG. 7 is a series of graphs comparing, for perfused con-
structs (open bars) and control constructs (filled bars) with 
respect to time, A) live cell number per construct; B) viability 
of cells on the construct (Dashed line represents the viability 
of freshly isolated cells: 83.8+/-2.0 (n=6); C) molar ration of 
lactate produced to glucose consumed; D) glucose consump-
tion rate in micromoles per hour per 10 6 cells (Dashed line 
represents reported values of the glucose consumption rate, 
Casey, et al., Circulation, 102: 3124-3129, 2000); E) lactate 
dehydrogenase (LDH) content (in units) in culture medium (P 
values were calculated by two-way ANOVA in conjunction 
with Tukey's test for pair wise multiple comparisons (n=3-9 
samples per data point). Differences were considered signifi-
cant if P<0.05. *Significant difference between perfused and 
dish-grown constructs; #significant difference between l-
and 7-day or 1.5 hour constructs; &significant difference 
between 7- and 1-day constructs) 
FIG. 8 is a series of graphs showing, with respect to time, 
tie fraction of cells from A) perfused constructs and B) dish-
grown constructs, the fraction of cells in the G o/G, (open bar), 
S (light gray bar) and G z/M (dark gray bar) phases of the cell 
cycle. (P values calculated as for FIG. 7; #Significant differ-
ence between the fractions of cells within the orbital dish 
group; *Significant difference between the corresponding 
perfused and dish-grown constructs). 
FIG. 9 is a set of micrographs illustrating the distribution of 
sarcomeric alpha-actin expressing cells at the periphery (top) 
and in the interiors (bottom) of constructs cultivated in per-
fused cartridges (left) or in orbitally mixed dishes (right) 
(scale bar-- 100 micron). 
FIG. 10 is a set of micrographs illustrating A) tissue archi-
tecture and B) cell differentiation through immunohis-
tochemical staining of three contractile proteins in native 
neonatal rat ventricles and 7-day constructs seeded and cul-
tured either in perfused cartridges or in orbitally mixed dishes 
(A: scale bar-300 micron); the images in B (scale bar-50 
micron) are higher magnification views of the areas in the 
boxes in A. 
FIG. 11A is a phase contrast micrograph of P2 mesenchy-
mal stem cells (MSC) at approximately 60-70% confluence. 
Original magnification 20x. 
FIG. 11B is a graph showing the expression of CD105 
surface marker in P2 MSC. 
FIG. 12 is a set of micrographs showing the expression of 
A) cardiac troponin I and B) connexin 43 (connexin: green; 
nuclei: blue) in human MSC seeded on collagen sponges after 
two weeks of culture with electrical stimulation (5V, 60 bpm, 
biphasic pulses 2 ms in duration). Scale bar -50 micron. 
DEFINITIONS 
The terms "engineered tissue/construct", "tissue-engi-
neered construct", and "bioartificial tissue/construct" are 
used herein interchangeably. They refer to a tissue or organ 
8 
that is produced, in whole or in part, using tissue engineering 
techniques. Exemplary descriptions of these techniques have 
been published (see, for example, "Principles ofTissue Engi-
neering, 2"d Edition", R. Lanza, R. Langer, and J. Vacanti 
5 (Eds.), Academic Press, 2000; "Methods of Tissue Engineer-
ing", A. Atala and R. Lanza (Eds.), Academic Press, 2001; 
"Animal Cell Culture", Masters (Ed.), Oxford University 
Press: New York, 2000; U.S. Pat. No. 4,963,489 and related 
U.S. patents). 
io 	 The term "biomimetic electrical stimulation", as used 
herein, refers to an electrical stimulus that is applied to a 
tissue construct either in vitro (during cultivation and forma-
tion of the construct) or in vivo (following implantation of the 
construct into an individual in need thereof). The electrical 
15 stimulation applied to the tissue-engineered construct is such 
that it resembles the electrical stimulation received by a spe-
cific native tissue in vivo. For example, cardiac tissue con-
structs of the invention may be cultivated in the presence of an 
electrical stimulation that mimics the electrical stimulation 
20 received by a cardiac muscle tissue in vivo. 
As used herein, the term "structural and functional charac-
teristics of a native tissue" refers to the anatomical (structural) 
and physiological (functional) characteristics exhibited by a 
construct that resemble the properties of an intact (i.e., not 
25 damaged, failing or deficient) native tissue in vivo. These 
properties include three-dimensional organization as well as 
physiological functions and responses. 
The term "treatment" is used herein to characterize a 
method that is aimed at (1) delaying or preventing the onset of 
3o a medical condition; or (2) slowing down or stopping the 
progression, aggravation, or deterioration of the symptoms of 
the condition; or (3) bringing about ameliorations of the 
symptoms of the condition; and/or (4) curing the condition. 
The treatment may be administered prior to the onset of the 
35 disease, for a prophylactic or preventive action. It may also be 
administered after initiation of the disease, for a therapeutic 
action. 
The terms "individual" and "patient" are used herein inter-
changeably. They refer to a human or another mammal, that 
40 suffers from tissue deficiency, damage or loss. In one embodi-
ment, the deficiency, damage and/or loss affect(s) a native 
tissue that contains electrically excitable cells and is subject 
to electrical stimulation in vivo. 
The term "implantation" refers to the medical operation by 
45 which an organ, group of cells, mechanical device or bioar-
tificial tissue construct is put into the body of an individual. 
The term "integration", as used herein, refers to a direct 
functional and structural connection between native host tis-
sue and implanted engineered construct(s). 
50 	 The term "histocompatibility" refers to the degree of simi- 
larity between the histocompatibility antigens of two indi-
viduals. Histocompatibility determines whether an organ 
transplant or engineered construct implant will be tolerated or 
rejected by the recipient's body. 
55 	 As used herein, the term "hemocompatibility" refers to the 
ability of any material, mechanical device or tissue-engi-
neered construct to be in contact with blood without interact-
ing with any blood components so as to cause their inappro-
priate activation or destruction. Hemocompatible medical 
6o devices or materials do not trigger adverse reactions such as 
platelet attachment, platelet activation, and complement acti-
vation that eventually lead to fibrin production and clot for-
mation. Agents that enhance hemocompatibility include, but 
are not limited to, anticoagulants such as heparin and war- 
65 farin. 
The term "biocompatible", as used herein, is intended to 
describe any material which upon implantation does not pro- 
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voke an undesirable adverse response in the patient (i.e., an 
undesirable reaction other than the expected response to the 
trauma of implantation). When introduced into a patient, a 
biocompatible material is not toxic or harmful to that patient, 
and does not cause immunological rejection. 
The term "biodegradable", as used herein, refers to the 
ability of materials to degrade under physiological conditions 
to form a product that can be metabolized or excreted without 
damage to organs. Biodegradable materials are not necessar-
ily hydrolytically degradable and may require enzymatic 
action to fully degrade. Biodegradable materials also include 
materials that are broken down in cells. 
The term "extracellular matrix" refers to a complex, three-
dimensional network of macromolecules (such as proteins) 
that provides an architectural scaffold for cellular adhesion 
and migration. 
In the context of the present invention, cells are organized 
on a substrate "with a defined orientation" when their spatial 
organization on the substrate is non-random. 
The term "gap junction", as used herein, refers to a junction 
between two cells, which consists of pores that allow the 
passage of small molecules (up to 9 kDa) from the cytoplasm 
of one cell to the cytoplasm of another cell. 
The term "connexin" refers to the main protein component 
of a connexon, the structural subunit of a gap junction (six 
connexins make up one connexon). 
The term "cell proliferation" refers to an expansion of a 
population of cells by the continuous division of single cells 
into two identical daughter cells. 
The term "cell differentiation", as used herein, refers to the 
elaboration of particular characteristics that are expressed by 
an end-stage cell type or a cell en route to becoming an 
end-stage cell (i.e., a specialized cell). The term "directed 
differentiation" refers to a process of manipulating cell cul-
ture conditions to induce differentiation into a particular cell 
type. The term "cell trans-differentiation" refers to the pro-
cess by which a cell changes from one state of differentiation 
to another. 
The term "stem cell' refers to a relatively undifferentiated 
cell that has the capacity for sustained self-renewal, often 
throughout the lifetime of an animal or human, as well as the 
potential to give rise to differentiated progeny (i.e., to differ-
ent types of specialized cells). An "embryonic stem cell' is a 
stem cell derived from a group of cells called the inner cell 
mass, which is part of the early (4 to 5 days old) embryo called 
the blastocyst. Once removed from the blastocyst, the cells of 
the inner cell mass can be cultured into embryonic stem cells. 
In the laboratory, embryonic stem cells can proliferate indefi-
nitely, a property that is not shared by adult stem cells. An 
"adult stem cell" is an undifferentiated cell found in a differ-
entiated (specialized) tissue. Adult stem cells are capable of 
making identical copies of themselves for the lifetime of the 
organism. Adult stem cells usually divide to generate pro-
genitor or precursor cells, which then differentiate or develop 
into "mature" cell types that have characteristic shapes and 
specialized functions. Sources of adult stem cells include 
bone marrow, blood, the cornea and retina of the eye, brain, 
skeletal muscle, dental pulp, liver, skin, the lining of the 
gastrointestinal tract, and pancreas. 
The term "pluripotent stem cell' refers to a stem cell that 
has the ability to give rise to types of cells that develop from 
the three germ layers (mesoderm, endoderm, and ectoderm) 
from which all the cells of the body arise. 
The term "plasticity" refers to the ability of an adult stem 
cell from one tissue to generate the specialized cell type(s) of 
another tissue. 
10 
The terms "progenitor cell' or "precursor cell' are used 
herein interchangeably. They refer to a cell that occurs in fetal 
or adult tissue and is partially specialized; it divides and gives 
rise to differentiated cells. Precursor cells belong to a transi- 
5 tory amplifying population of cells derived from stem cells. 
Progenitor cells do not have the capacity for sustained, undif-
ferentiated self-renewal. 
Additional definitions are provided throughout the 
Detailed Description. 
10 
DETAILED DESCRIPTION OF CERTAIN 
PREFERRED EMBODIMENTS 
The present invention is directed to improved strategies for 
15 the creation ofbioartificial tissues. More specifically, systems 
are described that allow for the formation of three-dimen-
sional tissue-engineered constructs having structural and 
functional characteristics of a native tissue. In particular, the 
invention provides preparation methods for the production of 
20 bioartificial equivalents of native tissues that contain electri-
cally excitable cells and are subject to electrical stimulation in 
vivo. Examples of such native tissues include cardiac muscle 
tissue, striated skeletal muscle tissue, smooth muscle tissue, 
bone, vasculature, and nerve tissue. 
25 I. Preparative Methods of Three-dimensional Tissue-engi-
neered Constructs 
In one aspect, the present invention provides preparation 
methods for three-dimensional tissue-engineered constructs 
which include the steps of contacting a suitable substrate with 
30 mammalian cells to form a cell-seeded construct, and culti-
vating the resulting cell-seeded construct in vitro in the pres-
ence of a biomimetic electrical stimulation. The in vitro cul-
tivation is carried out under conditions and for a time period 
such that they allow the formation of a three-dimensional cell 
35 structure, which exhibits structural and functional character-
istics of a native tissue. 
Substrate 
As mentioned above, cells placed in culture typically adopt 
a two-dimensional monolayer configuration that is random, 
4o disordered and different from that of cells within a native 
tissue. In tissue engineering techniques, a substrate is used to 
stimulate a more in vivo-like organization of the cells and 
facilitate the creation of new functional tissue in three dimen-
sions. More specifically, substrates serve as templates to 
45 which seeded cells can attach or adhere and provide the cells 
with the biomechanical support they initially need to grow, 
differentiate, produce their own extracellular matrix, and 
organize into three-dimensional structures representative of 
native tissue. 
50 	 To facilitate cell metabolism, the substrate may include a 
porous three-dimensional scaffold including an intercon-
nected pore network for cell/tissue growth and flow transport 
of nutrients, oxygen and metabolic waste. The substrate 
should be compatible with the types of cells that are used in 
55 the preparation of the construct and should exhibit a suitable 
surface chemistry for cell attachment, proliferation and/or 
differentiation. Substrate materials that are easily processed 
will allow the formation of a variety of shapes and sizes. 
The selection of a substrate for use in the preparative meth- 
60 ods of the invention will depend on the intended purpose of 
the tissue-engineered construct. Different properties of the 
support material may be considered. These properties 
include, but are not limited to, biocompatibility, biodegrad-
ability, tensile strength, flexibility, elasticity, and cost. For 
65 example, when the engineered construct is intended to be 
used as a medical implant, the material should be biologically 
compatible for implantation into an individual. Furthermore, 
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the substrate may display mechanical properties that match 
those of the native tissues at the site of implantation. Addi-
tionally or alternatively, it may be desirable to control the 
degradation and resorption rate of the support material to 
match cell/tissue growth in vitro and/or in vivo. Similarly, the 
size and geometry of the substrate, which will directly influ-
ence the dimensions and shape of the final engineered con-
struct, will be selected based on the intended use of the 
construct. Substrates in the form of a mesh, foam, gel, sponge, 
suture and the like have routinely been used in tissue engi-
neering. 
Suitable substrates for use in the practice of the preparative 
methods of the present invention may include a naturally-
occurring polymer, a synthetic polymer, or a combination of 
natural and/or synthetic polymers. 
Naturally-occurring polymers include polysaccharides 
and proteins. Exemplary polysaccharides include starches, 
dextrans, celluloses, hyaluronic acid and its derivatives; 
exemplary proteins include collagen and gelatin. Polysaccha-
rides such as starches, dextrans, and celluloses may be 
unmodified or may be modified physically or chemically to 
affect one or more of their properties such as their character-
istics in the hydrated state, their solubility, or their half-life in 
vivo. 
In certain embodiments, the substrate includes a biocom-
patible, degradable polymer. Such polymers can be broken 
down by cellular action and/or by action of non-living body 
fluid components. A variety of biocompatible, degradable 
polymers are suitable for use in the preparation methods of 
the present invention. These include, but are not limited to, 
polyanhydrides, polyorthoesters, polyphosphazenes, polyca-
prolactones, polyamides, polyurethanes, polyesteramides, 
polydioxanones, polyacetals, polyketals, polycarbonates, 
polyorthocarbonates, polyhydroxybutyrates, polyhydroxy-
valerates, polyalkylene oxalates, polyalkylene succinates, 
poly(malic acid), poly(amino acids), poly(methyl vinyl 
ether), poly(maleic anhydride), chitin, chitosan, and copoly-
mers, terpolymers, or higher poly-monomer polymers 
thereof, or combinations or mixtures thereof. 
In other embodiments, the polymer includes polyhydroxy 
acids such as polylactic acid (PLA), polyglycolic acid (PGA), 
their copolymers poly(lactic-co-glycolic acid) (PLAGA), 
and mixtures of any of these. These polymers are among the 
synthetic polymers approved for human clinical use as surgi-
cal suture materials and in controlled release devices. They 
are degraded by hydrolysis to products that can be metabo-
lized and excreted. Furthermore, copolymerization of PLA 
and PGA offers the advantage of a large spectrum of degra-
dation rates from a few days to several years by simply vary-
ing the copolymer ratio of glycolic acid to lactic acid which is 
more hydrophobic and less crystalline than PGA and 
degrades at a slower rate. 
Mammalian Cells 
Suitable mammalian cells for use with the inventive meth-
ods of preparation of three-dimensional tissue-engineered 
constructs are cells that have a native capacity for differen-
tiation into a particular tissue or cells that may be manipulated 
into forming a particular tissue. Therefore, suitable mamma-
lian cells include neonatal cells, autologous or heterologous 
adult or aged donor cells, progenitor or precursor cells, and 
stem cells as long as they can be manipulated to form a given 
tissue. In one embodiment, the mammalian cells are (or can 
become, for example, after differentiation) electrically excit-
able. 
Exemplary mammalian cells for use with the preparative 
methods of the present invention include mouse, rat, rabbit, 
guinea pig, hamster, cow, pig, horse, goat, sheep, dog, cat and 
12 
human cells. The cellular composition used in the preparation 
may be varied depending on the intended purpose of the 
three-dimensional tissue-engineered construct. In certain 
embodiments, the mammalian cells are of a single cell type. 
5 In other embodiments, the mammalian cells are of at least two 
different cell types. For example, a cardiac muscle construct 
may be made up of cardiac myocytes only. Alternatively, 
myocardial cells, endocardial cells, vascular smooth muscle 
cells, vascular endothelium, fibroblasts, and adrenergic cells, 
to or various subsets of those cell types may be co-cultured and 
used to prepare an organotypic structure resembling cardiac 
tissue. In addition, the mammalian cells used in the produc-
tion of the construct may come from a single individual, from 
15 different individuals of the same species, or different indi-
viduals of different species. The cells may also be genetically 
engineered to, for example, contain a gene of interest such as 
a gene expressing a growth factor. 
Tissue precursor cells can be obtained directly from a 
20 patient, from a culture of cells from a donor, or from estab-
lished cell culture lines. 
Examples of established cell lines that can be used in the 
preparation of electrically excitable tissue constructs include, 
but are not limited to, HL-1, AT-1, PC 12, and C2C12 cells. 
25 C2C12 cells were originally derived from skeletal myoblasts 
(satellite cells, S. W. Robinsong et al., Cell Transplant, 1996, 
5: 77-91) and are known to be able to trans-differentiate, 
acquiring characteristics of cardiac myocytes, such as the 
expression of connexin-43 (the major protein of cardiac gap 
30 junctions) and the formation of desmosomes at cell junctions. 
The PC 12 rat pheochromocytoma cell line is widely used to 
study neuronal differentiation by growth factors. In response 
to nerve growth factors and basic fibroblast growth factors, 
35 PC 12 cells acquire the phenotype of mature sympathetic 
neurons and become electrically excitable. HL-1 cells, 
derived from a mouse atrial cardiomyocyte tumor, are able to 
proliferate and can be serially passaged while retaining the 
phenotypic characteristics of the adult cardiomyocytes (W. C. 
40 Claycomb et al., Proc. Natl. Acad. Sci. USA, 1998, 95: 2979- 
2984). AT-1 cells are a transplantable tumor lineage derived 
from transgenic mouse atrial cardiomyocytes (M. E. Stein- 
helper et al., Am. J. Physiol. 1990, 259: H1826-H1834). 
These cells have the capacity to divide in culture and maintain 
45 a highly differentiated cardiac phenotype. More specifically, 
cultured AT-1 cells express adult cardiac-specific proteins 
(a-myosin heavy chain and sarcomeric a-actin) and connexin 
43, they exhibit ultrastructural features of cardiomyocytes 
(such as sarcomers, transverse tubules, and intercalated 
5o disks), and they have characteristic cardiac electrophysi- 
ological properties. All these cell lines are of animal origin. 
Suitable mammalian cells for use with the preparative 
methods of the invention may alternatively be obtained from 
the patient to be treated or from a donor. Ideally, when the 
55 construct is to be used as a medical implant, a biopsy of the 
patient's own tissue is obtained. Cells can be isolated from a 
healthy tissue adjacent defective tissue, or from other sites of 
healthy tissue in the patient. For example, precursor cells 
from healthy section of a heart that has been damaged or is 
6o deficient may be harvested. The construct formed using these 
harvested cells may then be introduced to the damaged/de- 
fective area of the patient's heart via implantation. Alterna- 
tively, or in addition, mesenchymal stem cells may be har- 
vested from a patient's or a donor's bone marrow. The main 
65 advantage of autologous cells is that they do not elicit an 
immunologic reaction in the patient. Alternatively, when the 
use of autologous cells is not feasible, cells of the same 
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species and preferably of the same immunological profile can 	 571-578; Q. Shi et al., Blood, 1998, 92: 362-367) and brain 
be obtained by biopsy, for example, from a patient's close 	 (E. Mezey et al., Science, 2000, 290: 1779-1782; T. R. Bra- 
relative. 	 zelton et al., Science, 2000,290:1775-1779; M.A. Eglitis and 
Heterologous cells can be obtained from donor organs. 	 E. Mezey, Proc. Natl. Acad. Sci. USA, 1997, 94: 4080-4085). 
Donor tissue from individual biopsies, surgical remnants, or 5 Similarly, enriched or purified hematopoietic stem cells were 
whole donor organs can be used as cell sources for the prepa- 	 reported to generate skeletal muscle (E. Gussoni et al., 
ration of tissue constructs. This procedure allows the genera- 	 Nature, 1999, 401: 390-394), cardiac muscle (K. A. Jackson 
tion of a large number of constructs using cells from a single 	 et al., J. Clin. Invest. 2001, 107: 1395-1402; D. Orlic et al., 
donor, and therefore significantly decreases the demand for 	 Proc. Natl. Acad. Sci. USA, 2001, 98:10344-10349; D. Orlic 
donor organs. However, heterologous cells may elicit an io et al., Science, 2001, 410: 701-705), endothelial cells (K. A. 
immune reaction in the recipient and require that the patient 	 Jackson et al., J. Clin. Invest. 2001, 107: 1395-1402), liver 
be immunosuppressed. Although immunosuppression can 	 hepatocytes and bile duct (E. Lagasse et al., Nat. Med. 2000, 
easily be achieved, for example, by using a schedule of ste- 	 6: 1229-1234), as well as multiple epithelial tissues (D. S. 
roids and other immunosuppressant drugs such as cyclospo- 	 Krause et al., Cell, 2001, 105: 369-377). 
rine, it is known to have many adverse side effects. 	 15 	 Stem cells derived from bone marrow, whether multipotent 
The cells harvested from donors are grown in culture using 	 hematopoietic stem cells or other tissue specific stem cells 
standard cell techniques and conditions, and are utilized when 	 resident in the bone marrow, have a major advantage over 
needed. Except for cardiac myocytes, which have limited 	 stem cells from other organs: they are well defined and easy to 
proliferation potential, cells are cultured only until a suffi- 	 isolate. Moreover, transplantation of bone marrow or hemato- 
cient number of cells have been obtained for a particular 20 poietic stem cells was also found to induce donor tolerance, 
application. Cells from biopsies are harvested, cultured, and 	 allowing trans-differentiation or transplantation of other tis- 
then isolated, pre-plated or selected using specific markers to 	 sue specific stem cells from the same donor without the need 
remove undesired cells types. 	 for prolonged immuno suppression of the recipient. In addi- 
Cell viability can be determined using standard techniques 	 tion, cells may be isolated from bone marrow without further 
including histology, quantitative assessment with radioiso-  25 injuring healthy tissue near the site being repaired using the 
topes, or visual observation using a light or scanning electron 	 techniques described herein. 
microscope or a fluorescent microscope. The biological func- 	 In particular, mesenchymal stem cells, which reside within 
tion of the cells delivered to the support structure can be 	 the bone marrow cavity, have been shown, both in culture and 
determined using a combination of the above techniques and 
	
following inj ection into particular tissues in mammals, to give 
standard functional assays. 	 3o rise to a range of cell types including chrondrocytes, osteo- 
Different cell types may be harvested from a patient or a 	 blasts, adipocytes, cardiac and skeletal muscle cells (K. W. 
donor. For example, when the inventive preparative methods 	 Liechty et al., Nat. Med. 2000, 6: 1282-1286; M. F. Pittenger 
are applied to produce a three-dimensional tissue-engineered 	 et al., Science, 1999, 284: 143-147), as well as cells typical of 
cardiac muscle construct, the mammalian cells may include 	 the central nervous system, such as neurons and astrocytes 
cardiomyocytes, endocardial cells, cardiac adrenergic cells, 35 (G. C. Kopen et al., Proc. Natl. Acad. Sci. USA, 1999, 96: 
cardiac fibroblasts, vascular endothelial cells, smooth muscle 	 10711-10716; D. Woodbury et al., J. Neurosci. Res. 2000,61: 
cells, and combinations of any of these. 	 364-370). Isolation, purification and culture expression of 
Alternatively, stem cells, which can provide a virtually 	 human mesenchymal stem cells are describedin U.S. Pat. No. 
never-ending supply of cells for tissue engineering, may be 	 6,387,369. 
used in the preparative methods of the invention. The advan-  40 	 The microenvironment (including contact with surround- 
tage of embryonic stem cells as a cell source, include virtually 	 ing cells, formation of extracellular matrix, nature of local 
indefinite growth and differentiation potential that encom- 	 milieu as well as presence of growth and differentiation fac- 
passes all cells and tissues. Specific differentiation in vitro 	 tors) plays a role in determining the stem cells' function. Stem 
into cells with the phenotypic characteristics of cardiomyo- 	 cell cultures can be treated under conditions and/or in the 
cytes, neural cells, insulin producing beta cells, and hemato-  45 presence of specific factors and agents that drive differentia- 
poietic cells has been demonstrated. 	 tion along a predetermined lineage. A selectable marker 
The discovery that some stem cell populations isolated 	 under the control of a lineage-specific promoter, for example, 
from adult tissues exhibit some degree of plasticity has 	 a transcription factor that is switched on early during lineage- 
opened new avenues for basic biological research and the 	 specific differentiation, may be inserted into the stem cells. 
development of novel therapies and clinical tools. The so- 5o The selectable marker will then be expressed in cells under- 
called adult stem cells can be derived from a variety of spe- 	 going differentiation into the lineage in question, and, by 
cific tissues to provide, for example, mesenchymal, neuronal 	 applying the selective agent, it is possible to kill off other cell 
and endothelial stem cells. 	 types in the cultures. 
There has been a plethora of reports suggesting that primi- 	 For example, U.S. Pat. No. 6,387,369 describes a series of 
tive stem cells within whole bone marrow possess greater 55 specific treatments applicable to mesenchymal stem cells to 
functional plasticity than was previously suspected. After 	 induce expression of cardiac specific genes. The conditions 
bone marrow transplantation into animals, donor-derived 	 that are disclosed are effective on rat, canine, and human 
stem cells have been found in such diverse non-hematopoietic 	 mesenchymal stem cells. Mesenchymal stem cells that 
tissues as skeletal muscle (G. Ferrari et al., Science, 1998, 	 progress towards cardiomyocytes first express proteins found 
279: 1528-1530), cardiac muscle (R. E. Bittner et al., Anat. 60 in fetal cardiac tissue and then proceed to adult forms. Detec- 
Embryol. 1999, 199: 391-396), liver (B. E. Petersen et al., 	 tion of expression of cardiomyocyte- specific proteins can be 
Science, 1999, 284: 1168-1170; E. Lagasse et al., Nat. Med. 	 achieved by using antibodies to, for example, myosin heavy 
2000, 6: 1229-1234; B. E. Petersen et al., Science, 1998, 284: 	 chain monoclonal antibody ME 20 or sarcoplasmic reticulum 
1168-1170; N. D. Theise et al., Hepatology, 2000, 31: 1235- 	 calcium ATPase. 
1240; N. D. Theise et al., Hepatology, 2000, 32: 11-16), 65 	 Mesenchymal stem cells may also be genetically modified 
vascular endothelium (T. Asahara et al., Science, 1997, 275: 	 or engineered to express proteins of importance for the dif- 
964-967; G. C. Schatteman et al., J. Clin. Invest. 2000, 106: 	 ferentiation and/or maintenance of striated skeletal muscle 
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cells. Exemplary proteins include growth factors (e.g., TGF-
P, IGF-1, FGF), myogenic factors (e.g., myoD, myogenin, 
Myf5, MRF), transcription factors (e.g., GATA-4), cytokines 
(e.g., cardiotropin-1), members oftheneuregulin family (e.g., 
neuregulin 1, 2, and 3) and homeobox genes (e.g., Csx, tin- 5 
man, NKx family). 
Other mammalian cells that can be used in the preparation 
methods of the present invention include precursor cells. 
Usually, between the stem cell and its terminally differenti-
ated progeny state, there is an intermediate population of io 
committed progenitors with limited proliferative capacity 
and restricted differentiation potential. These cells, called 
progenitor or precursor cells, are sometimes known as transit 
amplifying cells. 
Several reports (D. J. Prockop et al., Science, 1997, 276: 15 
71-74; D. J. Rickard et al., Dev. Biol. 1994,161: 218-228, A. 
J. Friedenstein et al., Cell Tissue Kinet. 1987, 20: 263-272; G. 
Ferrari et al., Science, 1998,279:1528-1530; A. Umezawa et 
al., J. Cell. Physiol. 1992, 151: 197-205; B. A. Ashton et al., 
Clin. Orthop. 1980, 151: 294-307; S. Makino et al., J. Clin. 20 
Invest. 1999, 103: 697-705) have, for example, revealed that 
marrow stromal cells havemany characteristics ofinesenchy-
mal stem cells. Pluripotential progenitor marrow stromal 
cells may differentiate into various cell types, including bone 
(D. J. Rickard et al., Dev. Biol. 1994, 161: 218-228, A. J. 25 
Friedenstein et al., Cell Tissue Kinet. 1987, 20: 263-272), 
muscle (S. Wakitani et al., Muscle Nerve, 1995, 18: 1417-
1426; G. Ferrari et al., Science, 1998, 279: 1528-1530), fat 
(A. Umezawa et al., J. Cell. Physiol. 1992, 151: 197-205), 
oval hepatocytes (B. E. Petersen et al., Science, 1999, 284: 30 
1168-1170), tendon or cartilage (B. A. Ashton et al., Clin. 
Orthop. 1980, 151: 294-307), and cardiomyocytes (S. 
Makino et al., J. Clin. Invest. 1999,103: 697- 705; D. Orlic et 
al., Nature, 2001, 938: 221-229). 
Progenitor cells that can be used for the preparation of 35 
bioartificial equivalents of cardiac muscle tissue, striated 
skeletal muscle tissue, smooth muscle tissue, bone, vascula-
ture, and nerve tissue are known in the art. 
Cultivation of Cell-Seeded Construct 
After preparation as described above, mammalian cells are 40 
seeded onto a three-dimensional substrate, and the resulting 
cell-seeded construct is immersed in medium in a culture dish 
or bioreactor (R. L. Carrier et al., Biotechnol. Bioeng. 1999, 
64: 580-589; J. Leor et al., Circulation, 2000, 102: 11156- 
11161; R. K. Li et al., Circulation, 1999, 100: II63-II69; M. 45 
Papadaki et al., Am. J. Physiol: Heart Circ. Physiol. 2001, 
280: H168-H178). 
The in vitro cultivation of cell-seeded substrates may be 
carried out by any method that leads to the formation of 
three-dimensional tissue constructs exhibiting properties 50 
characteristic of a native tissue. More specifically, the seeding 
protocol, bioreactor and cultivation conditions, which will 
influence the structural and functional characteristics of the 
final tissue-engineered construct, should be selected to pro-
vide an ideal environment for in vitro tissue growth. For 55 
example, in the case of a cardiac tissue construct, the in vitro 
system of choice needs to provide an oxygen supply to the 
cells at all times during cell seeding and construct cultivation. 
To this end, polymer scaffolds for cardiac tissue engineer-
ing have been seeded using a variety of techniques. For 60 
example, concentrated cell suspensions have been added to 
scaffolds (R. K. Li et al., Circulation, 1999, 100:1163-1169; R. 
K. Li et al., J. Thorac Cardiovasc. Surg. 2000, 119: 368-375). 
Suspensions of cardiomyocytes have also been seeded onto 
substrates in orbitally mixed dishes (R. L. Carrier et al., 65 
Biotechnol. Bioeng. 1999, 64: 580-589), in spinner flasks (N. 
Bursac et al., Am. J. Physiol. 1999, 277: H433-H444; R. L. 
Carrier et al., Biotechnol. Bioeng. 1999, 64: 580-589), and in 
rotating vessels (M. Papadaki et al., Am. J. Physiol: Heart 
Circ. Physiol. 2001, 280: H168-H178). 
Although all these methods resulted in constructs with 
viable cells, the cell distribution was highly inhomogeneous. 
Cardiac constructs cultured in well-mixed medium had an 
approximately 100 µm-thick peripheral tissue-like region 
around a relatively cell-free interior, a structure consistent 
with the presence of concentration gradients within the tissue. 
This is most likely due to the fact that, in these systems, the 
oxygen dissolved in the medium is transported to the cells by 
molecular diffusion, which provides enough oxygen for a thin 
outer layer of functional tissue but not to the construct inte-
rior, which remains relatively acellular (N. Bursac et al., Am. 
J. Physiol. 1999, 277: H433-H444; R. L . Carrier et al., 
Biotechnol. Bioeng. 1999, 64: 580-589; M. Papadaki et al., 
Am. J. Physiol: Heart Circ. Physiol. 2001, 280: H168-H178; 
W. H. Zimmermann et al., Biotechnol. Bioeng. 2000, 68: 
106-114). 
Thus, whereas human heart muscle is up to 2 centimeters 
thick, growth of bioartificial tissue equivalents in bioreactors 
typically stops once the construct is about 100 µm thick, i.e., 
about 4 to 7 cell layers thick. Beyond this thickness, the 
innermost cells are too far from the supply of fresh growth 
medium to thrive. The formation of 1 to 5 mm thick, func-
tional constructs based on cells that cannot tolerate hypoxia 
for prolonged periods of time (for example, cardiac myo-
cytes) depends on the ability to seed the cells at a high and 
spatially uniform initial density as well as on the capacity to 
maintain their viability and function. Therefore, in order to 
engineer tissue constructs with a certain threshold thickness, 
uniformity of tissue architecture and functionality, it is nec-
essary to overcome oxygen diffusional limitations during 
both the steps of scaffold seeding and of construct cultivation. 
In one embodiment, scaffolds are 1.5 mm thick (dry thick-
ness) or greater, for example, at least 2 mm, at least 3 mm, or 
at least 4 mm thick. 
In order to enhance mass transport between culture 
medium and cells within cultured constructs, perfused biore-
actor systems have been developed (R. L. Carrier et al., Bio-
technol. Bioeng. 2002, 78: 617-625; R. L. Carrier et al., 
Tissue Eng. 2002, 8: 175-188). In these systems, cells are 
seeded onto a scaffold in tissue culture dishes for 2 to 3 days 
and subsequently cultured for about 1 week in a bioreactor 
that forces the nutrient medium to perfuse directly through 
the cell-seeded construct instead of simply flowing around it. 
The transport of oxygen from the medium to the cells occurs 
via diffusion during cell seeding and by a combination of 
diffusion and convection during cultivation, which better 
mimics the transport conditions within native tissue. Further-
more, during cultivation, the flow of medium redistributes the 
cells evenly across the entire volume of the construct, leading 
to homogenous spatial organization of the cells. However, in 
the tissue constructs obtained using these methods, the cell 
density remained low due to the limitations in oxygen trans-
port during the cell seeding step. 
A new seeding/cultivation strategy which combines the 
methods for rapid gel inoculation (G. A. Ameer et al., J. 
Orthop. Res. 2002, 20: 16-19) and direct medium perfusion 
through the seeded scaffold (S. S. Kim et al., Tissue Eng. 
2000, 6: 39-44) has recently been developed in the applicant's 
laboratory and found to result in high rate, yield, viability and 
uniformity of cell seeding (M. Radisic et al., Biotechnol. 
Bioeng. 2003, 82: 403-414). In these studies, cells (neonatal 
rat cardiomyocytes) were seeded at initial densities compa-
rable to those found in adult rat myocardium (i.e., -10 $ cells/ 
cm3 ; C. A. Mandarim-de-Lacerda and L. M. M. Pereira, 
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Pathobiology, 2000, 68: 36-42) into a Collagen sponge (13 
mmx3 mm discs), using Matrigel® as a vehicle for rapid cell 
delivery. Scaffolds inoculated with cell-gel suspension were 
then seeded in perfused cartridges with alternating medium 
flow. Medium perfusion through the cell-polymer construct 5 
was established immediately in order to maintain the viability 
of inoculated cells during cell attachment to substrates and 
subsequent construct cultivation. This strategy produced 
thick, compact and functional cardiac muscle tissue with 
more evenly distributed cells and much higher cell densities io 
than any previous study. 
In an exemplary perfusion system, a construct 30 is dis-
posed in a cartridge 32 between two stainless steel support 
screens 34 (FIG. lA). Silicone gaskets 35 protect the con-
struct 30 from the steel screens 34. The cartridge 32 is con- 15 
nected to a push/pull syringe pump 36. Each side of pump 36 
is connected to de-bubbling syringe 38 to remove airbubbles. 
Gas exchangers 40 allow regulation of the gasses dissolved in 
culture media circulated through the system. 
In all the methods described above, the cell-seeded con- 20 
struct is cultivated in a nutritive medium. Nutritive media for 
mammalian cell cultures are well known in the art. Generally, 
culture media contain essential nutrients, trace elements, vita-
mins, lipids, electrolytes, and sources of energy. Other addi-
tives include serum from fetal, new born or adult cows, 25 
growth factors, cytokines, and functional modulators. The 
choice of the culture medium and of its components, which 
affect the proliferation, growth, and function of cells and alter 
cell phenotype in culture, will depend on the mammalian cells 
used in the preparative methods. Media for the culture of 30 
mammalian cardiac cells are known in the art (see, for 
example, S. N. Mohamed et al., In Vitro Cell and Develop. 
Biol. 1983.19:471-478; P. Libby, J. Mol. Cell. Cardiol. 1984. 
16: 803-811; D. L. Freerksen et al., J. Cell. Physiol., 1984, 
120: 126-134; G. Kessler-Icekson et al., Exp. Cell Res. 1984. 35 
155: 113-120; J. S. Karliner et al., Biochem. Biophys. Res. 
Comm. 1985. 128: 376-382; T. Suzuki et al., FEBS Letters, 
1990, 268: 149-151; T. Suzuki et al., J. Cardiov. Pharmacol. 
1991, 17: S182-S186; T. Suzuki et al., J. Mol. Cell. Cardiol. 
1997, 29: 2087-2093). Different factors and agents may be 40 
added to the culture medium. In certain embodiments, the in 
vitro cultivation of the cell-seeded construct is carried out 
under conditions selected to promote deposition of extracel-
lular matrix components. The in vitro cultivation of the cell-
seeded construct may also be carried out under conditions 45 
that promote cell proliferation and/or cell differentiation. 
The cultivation dish or bioreactor is placed into an incuba-
tor, which provides a controlled environment. The tempera-
ture of the incubator is generally set at 37° C., and the relative 
humidity of the incubator is held at 90%. The composition of 50 
the gas environment in the incubator depends on the selection 
of the medium. For example, a mixture of air with 5% CO 2 
may be used in combination with a bicarbonate-buffered 
medium, while air alone may be used when a HEPES-buff-
ered medium is utilized. 55 
Tissue engineering methods often lead to bioartificial tis-
sue constructs, that, unlike native cardiac tissue, which con-
sists of parallel fibers with defined orientation, contain cells 
that exhibit random orientation and a poor degree of differ-
entiation. In order to achieve a more tissue-like organization 60 
of the cells on the substrate, the inventive methods include 
physiological electrical stimuli during in vitro culture that are 
thought to be necessary for proper development and differen-
tiation of native and engineered cardiac muscle. 
More specifically, the preparative methods of the invention 65 
may include cultivating the cell-seeded construct in the pres-
ence of a biomimetic electrical stimulation. Specific condi- 
tions of electrical stimulation (nature, amplitude, frequency) 
are designed to mimic the electrical stimulation received by a 
specific native tissue in vivo. For example, cardiac tissue 
constructs of the invention are preferably cultivated in the 
presence of an electrical stimulation that mimics the electrical 
stimulation received by a cardiac muscle tissue in vivo. 
In certain embodiments, the electrical stimulation is used 
to differentiate cardiac progenitor cells and/or stem cells into 
cardiac myocytes. Results from experiments carried out by 
the applicants suggest that when cardiac-like electrical stimu-
lation is applied during in vitro cultivation, there is no need 
for chemical factors (such as, for example, 5-azacytidine) to 
induce cell differentiation. Therefore, cardiac-like electrical 
stimulation of human mesenchymal stem cells can be used to 
generate cardiac-like cell phenotype without the application 
of any specific chemical factors. 
As illustrated in the Examples below, the inventive meth-
ods lead to the formation of cardiac muscle constructs with 
improved structural and functional characteristics. Inparticu-
lar, cardiac constructs cultivated in the presence of a biomi-
metic electrical stimulation were found to exhibit aligned 
nuclei and thick aligned myofibers expressing cardiac tropo-
nin I and sarcomeric a-actin, while constructs cultured in the 
absence of electrical stimulation (all other conditions being 
the same) consisted of mostly round, mononucleated cells 
with lower level of differentiation. 
The inventive preparation methods may be applied to pro-
duce bioartificial equivalents of other native tissues that con-
tain electrically excitable cells and are subject to electrical 
stimulation in vivo. Thus, the electrical stimulation used to 
form these tissue-engineered constructs may be chosen to 
mimic the electrical stimulation received by a striated skeletal 
muscle tissue, smooth muscle tissue, bone, vasculature, or 
nerve tissue in vivo. 
Characteristics of electrical stimulations received by native 
tissues in vivo are known in the art. The electrical stimulation 
may be generated by any suitable system. For example, com-
mercially available cardiac stimulators, which can produce 
electrical stimuli that mimic the electrical stimuli received by 
native cardiac tissues in vivo, may be used in the preparation 
of cardiac constructs. Other methods include using impulse 
generators in custom-made electric circuits. 
The progress of the formation of a tissue-engineered con-
struct may be assessed using different methods. For example, 
in the case of a cardiac muscle tissue construct, the sponta-
neous or stimulated contractile activity of the cultivated con-
struct may be determined non-invasively. Properties such as 
strength, elasticity, conductivity, tissue organization, cellular 
organization, cell viability, cell morphology, metabolic activ-
ity, cell cycle propagation, ultrastructural features, electrical 
signal propagation, gene expression and protein expression 
may be studied on small pieces of the cultivated construct. 
Alternatively or additionally, samples of the culture medium 
may be analyzed for the presence of metabolites and waste 
products. 
Once the culture has progressed enough that the cells 
exhibit the three-dimensional cellular organization of the 
desired tissue over a significant portion of the substrate, cul-
tivation of the construct may be stopped. Adequate incubation 
times and parameters which depend on the cells, medium and 
support used in the construct preparation can easily be deter-
mined by one skilled in the art. 
In addition to involving an electrical stimulation, the meth-
ods of preparation of the invention may further include the 
step of stimulating the cell-seeding construct mechanically 
and/or chemically. For example, Eschenhagen and coworkers 
have submitted cardiac patches formed using cardiac muscle 
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cells from newborn rats to stretching (C. Fink et al., FASEB J. 	 three-dimensional cell structure is obtained by contacting the 
2000, 14: 669-679), and have shown that when these engi- 	 substrate with mammalian cells to form a cell-seeded con- 
neered tissues are implanted into rats, they contracted up to 	 struct, and cultivating the resulting construct in vitro in the 
four times more vigorously than unstretched tissues (T. 	 presence of a biomimetic electrical stimulation. 
Eschenghagen et al., Transplant Immunol. 2002,9: 315-321). 5 	 Suitable substrates and cells as well as cultivation condi- 
Other examples of mechanical stimulation include strain, 	 tions for these, are as described above. When the construct is 
hydrostatic pressure, direct compression, "high-shear fluid 	 a cardiac muscle construct, the cells may include one or more 
environments", and "low-shear fluid environments". Multi- 	 of cardiomyocytes, endocardial cells, cardiac adrenergic 
directional mechanical stimulation may also be used. For 	 cells, cardiac fibroblasts, vascular endothelial cells, smooth 
example, a construct may be strained in one direction at its io muscle cells, cardiac progenitor cells, and stem cells. During 
comers and in a different direction in the center. In addition, 	 the cultivation period, the cell-seeded construct is submitted 
the mechanical stimulation may be constant or intermittent. 	 to an electrical stimulation that mimics the electrical stimu- 
For example, a pulsed mechanical stimulus to imitate the 	 lation received by a cardiac muscle tissue in vivo. Inventive 
contraction of heart muscle or of the flow of blood may be 	 cardiac constructs may have different shapes depending on 
applied. 	 15 their intended use. For example, they may be grown as pieces 
Chemical stimulation is often used during cultivation of 	 of tissue to be used as patches, or they may be grown to 
tissue engineering constructs to induce cell differentiation. 	 resemble heart valves. 
For example, marrow stromal cells have been shown to spon- 	 III. Therapeutic Uses of Inventive Constructs 
taneously start beating after exposure to 5-azacytidine, a 	 In another aspect, the present invention provides methods 
cytosine analog capable of altering expression of certain 20 for treating an individual suffering from tissue deficiency, 
genes that may regulate differentiation (S. Makino et al., J. 	 damage or loss. These methods may include producing a 
Clinical Invest. 1999, 103: 697-705). Similarly, agents used 	 three-dimensional tissue-engineered construct according to 
to induce neural differentiation from bone marrow or umbili- 	 the methods of preparation described above, implanting the 
cal cord blood include retinoic acid, (3-mercaptoethanol, anti- 	 construct into the individual in need thereof, and submitting 
oxidants, demethylating agents, compounds that increase 25 the implanted construct to a biomimetic electrical stimula- 
intracellular cyclic AMP (e.g., isobutylmethylxanthine), and 	 tion. The inventive methods of treatment are particularly use- 
physiological neural inducers (e.g, noggin) (7. R. Sanchez- 	 ful when the native tissue to be replaced or supplemented is 
Ramos, J. Neuroscience Res. 2002, 69: 880-893). 	 one which contains electrically excitable cells and is subject 
In other embodiments, the inventive preparative methods 	 to electrical stimulation in vivo. Examples of such tissues 
further include the step of treating the three-dimensional tis-  30 include, but are not limited to, cardiac muscle tissue, striated 
sue-engineered construct with at least one biologically active 	 skeletal muscle tissue, smooth muscle tissue, bone, vascula- 
agent. The biologically active agent may include one or more 	 ture, and nerve tissue. 
of growth factors, adhesion factors, soluble extracellular 	 The electrical stimulation applied to the construct in vivo 
matrix proteins, antibiotics, agents that enhance vasculariza- 	 following implantation may have several functions. It may 
tion, agents that enhance cell differentiation, agents that 35 enhance the integration of the engineered construct with host 
enhance tissue differentiation, agents that inhibit fibrosis, 	 tissue and allow the formation of a direct structural and func- 
agents that inhibit tumorigenesis, agents that enhance cell 	 tional connection between the implanted engineered con- 
proliferation, agents that inhibit cell proliferation, agents that 	 struct and the native host tissue. Additional or alternatively, 
inhibit scaffold degradation, agents that enhance scaffold 	 the electrical stimulation may increase cell survival and/or 
degradation, agents that enhance histocompatibility, and 40 cell functionality in vivo. 
agents that enhance hemocompatibility. Exemplary biologi- 	 In some embodiments, it may be desirable to prepare the 
cally active agents that may be exploited for use with the 	 construct and implant it without having first exposed the 
invention include but are not limited to activin A (ACT), 	 construct to a biomimetic electrical stimulation. Instead, the 
retinoic acid (RA), epidermal growth factor, bone morphoge- 	 construct is subjected to such stimulation after implantation. 
netic protein, platelet derived growth factor, hepatocyte 45 The construct is provided with a synthetic or natural lead to 
growth factor, insulin-like growth factors (IGF) I and II, 	 connect it to a source of electrical stimulation. For example, 
hematopoietic growth factors, peptide growth factors, eryth- 	 nervous tissue from elsewhere in the native tissue may be 
ropoietin, interleukins, tumor necrosis factors, interferons, 	 joined to the construct using standard surgical techniques. A 
colony stimulating factors, heparin binding growth factor 	 pacemaker may be implanted and connected to the construct, 
(HBGF), alpha or beta transforming growth factor (a- or 50 or the patient may carry an external power source connected 
R -TGF), fibroblastic growth factors, epidermal growth factor 	 to the implanted construct. 
(EGF), vascular endothelium growth (VEGF), nerve growth 	 In certain embodiments, the inventive methods are used for 
factor (NGF), muscle morphogenic factor (MMP), integrins, 	 treating an individual suffering from tissue deficiency, dam- 
and amino acid sequences including cell binding regions such 	 age or loss that is associated with an acute or chronic heart 
as RGD). 	 55 condition. Medical indications for such a treatment include 
The choice of the specific cultivation conditions will 	 coronary heart disease, cardiomyopathy, endocarditis, con- 
depend on the nature of the construct desired as well as on the 	 genital cardiovascular defects, and congestive heart failure. A 
intended purpose of the final tissue engineered product. In 	 final common pathway of many cardiovascular diseases is 
certain embodiments, after preparation, the construct is 	 irreversible damage of the cardiac muscle tissue. This effect is 
stored before being used. In other embodiments, the construct 60 generally attributed to the inability (or weak capacity) of 
is used immediately after preparation. 	 cardiac cells to replicate after injury (M. H. Soonpaa and L. D. 
II. Three-Dimensional Tissue-Engineered Constructs 	 Field, Circ. Res. 1998, 83: 15-26) as well as to the lack of a 
In an exemplary embodiment, the present invention is 	 substantial source of resident stem cells in the myocardium. 
directed to three-dimensional tissue-engineered constructs 	 Excessive loss of cardiomyocytes due to ischemia (defi- 
including mammalian cells organized on a substrate to pro-  65 ciency of blood flow) and formation of scar tissue are, for 
vide a three-dimensional cell structure having structural and 	 example, observed after myocardial infarction. Myocardial 
functional characteristics of a native tissue. Preferably, the 	 infarction is a leading cause of heart failure and death in 
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developed countries. According to the American HeartAsso- 	 from an artery from the chest or wrist is attached to the heart 
ciation, in 2000, approximately 1.1 million Americans suf- 	 artery above and below the narrowed area, thus making a 
fered from a myocardial infarction, usually as a result of a 	 bypass around the blockage. 
heart attack. Infarcts occur when a coronary artery becomes 	 These procedures substantially improve symptoms in more 
obstructed and no longer supplies blood to the myocardial 5 than 90% of patients who undergo the treatment. A graft may 
tissue. The damage of myocardial infarction is generally pro- 	 be placed to any one of the following arteries: left main 
gressive (D. L. Mann, Circulation, 1999, 100: 999-1008). 	 coronary artery, which supplies the left ventricle of the heart; 
However, the consequences are often severe and disabling. 	 the left anterior descending artery; obtuse marginal branch of 
Immediate hemodynamic effects are followed by three major 	 the circumflex artery; circumflex artery; right coronary 
processes: infarct expansion, infarct extension, and ventricu-  io artery; and posterior descending artery. Better results are 
lar remodeling. The magnitude and clinical significance of 	 obtained if one of the patient's own vessels is grafted. If an 
these processes highly depend on the size and location of the 	 autologous vessel cannot be used, a prosthetic vessel may be 
myocardial infarction (H. F. Weisman and B. Healy, Prog. 	 implanted. However, synthetic grafts that are foreign to the 
Cardiovasc. Dis. 1987, 30: 73-110; S. T. Kelley et al., Circu- 	 body may pose long-term health risks. Furthermore, synthetic 
lation, 1999, 99: 135-142). 	 15 materials are not useful for the construction of the small 
Early after a myocardial infarction, infarct expansion takes 	 diameter grafts that are required for many heart bypass sur- 
place through slippage of the tissue layers, which results in a 	 geries, as the grafts are more prone to clotting. 
permanent regional thinning and dilation of the infract zone. 	 Therefore, inventive constructs in the shape of heart ves- 
Infarct extension corresponds to additional myocardial 	 sels, especially those prepared using autologous cells, appear 
necrosis and produces an increase in total mass of infarcted 20 as a potential alternative with several advantageous proper- 
tissue. The presence of infarcted tissue (i.e., scar tissue that is 	 ties, such as avoidance of anti-coagulant therapy, a potential 
unable to contract during systole) leads to a depression in 	 for growth as well as greater durability and longevity. 
ventricular function, and eventually to dysfunction in cardiac 	 Other medical indications for the inventive methods of 
tissue remote from the site of initial infarction. This greatly 	 treatment include congenital heart defects. When the heart or 
exacerbates the nature of the disease and can often progress 25 blood vessels near the heart do not develop normally before 
into advanced stages of congestive heart failure. The third 
	
birth, a condition called congenital defect occurs. Most heart 
process, ventricular remodeling, usually happens weeks or 	 defects cause an abnormal blood flow through the heart or 
years after myocardial infarction. It corresponds to a progres- 	 obstruct blood flow in the heart and vessels. Congenital heart 
sive enlargement of the ventricle with depression of ventricu- 	 defects include obstruction defects (such as aortic stenosis, 
lar function, and is believed to result from the high stress 30 pulmonary stenosis, bicuspid aortic valve, subaortic stenosis 
undergone by tissues surrounding the initial infarction zone 	 and coarctation of the aorta), septal defects (such as atrial 
(D. K. Bogen et al., Circulation Res. 1980, 47: 728-741; J. 	 septal defect, Ebstein's anomaly and ventricular septal 
Lessick et al., Circulation, 1991, 84: 1072-1086). Deteriora- 	 defect), cyanotic defects (such as tetraology of Fallot, tricus- 
tion of the ventricular function eventually leads to heart fail- 	 pid atresia and transposition of the great arteries), hypoplastic 
ure (D. L. Mann, Circulation, 1999, 100: 999-1008). 	 35 left heart syndrome and patent ductus arteriosus. 
Despite recent advances in the treatment of acute myo- 	 Depending on the specific heart defect experienced by the 
cardical infarction, the ability to repair extensive myocardial 	 patient, an inventive cardiac muscle patch or engineered heart 
damage and to treat heart failure is limited (D. L. Mann, 	 valve can be implanted to correct the heart's deficiency. 
Circulation, 1999, 100: 999-1008). A possible strategy to 	 Efficacy of these treatments can be monitored by clinically 
restore heart function after myocardial injury is to replace the 4o accepted criteria, such as reduction in area occupied by scar 
damaged tissue with healthy tissue. Experiments have shown 	 tissue or revascularization of scar tissue, and/or in an 
that the strategy of tissue engineering could be used for regen- 	 improvement in developed pressure, systolic pressure, end 
eration and healing of the infarcted myocardium and attenu- 	 diastolic pressure, patient mobility and quality of life. 
ation of wall stress, infarct expansion and left ventricle dila- 	 To determine the suitability of the methods of treatment 
tation. These beneficial effects could be translated into the 45 provided by the present invention, inventive three-dimen- 
prevention of heart failure progression (7. Leor et al., Circu- 	 sional constructs can first be tested in animal models. Tissue- 
lation, 2000, 102:11156-11161). 	 engineered constructs can, for example, be implanted into 
Inventive cardiac muscle constructs may be implanted into 	 immunodeficient animals (such as nude mice or other animals 
patients after myocardial infarction to provide for augmenta- 	 rendered immunodeficient chemically or by irradiation) and 
tion of cardiac tissue and contractile function. After implan-  50 the implanted construct(s) may be submitted to a biomimetic 
tation, such tissue-engineered constructs will act as ventricu- 	 electrical stimulation to enhance the integration of the grafted 
lar "patch" of functional cardiac tissue or "contracting living 	 tissue and increase cell survival and functionality in vivo. 
Band-Aid". One, or more than one, cardiac construct may be 	 Heart of small animal models can be cryoinjured by placing a 
implanted into, for example, infarcted area(s) of the heart to 	 precooled aluminum rod in contact with the surface of the 
help re-establish the correct propagation of the contractile 55 anterior left ventricle wall (C. E. Murry et al., J. Clin. Invest. 
signal and to provide contractile elements. 	 1996, 98: 2209-2217; H. Reinecke et al., Circulation, 1999, 
Inventive constructs in the shape of heart valves may find 
	
100: 193-202; U.S. Pat. No. 6,099,832). In larger animals, 
applications as blood vessel substitutes in heart bypass sur- 	 cryoinjury can be inflicted by placing a 30-50 mm copper disk 
gery. More than 500,000 coronary artery bypass operations 	 probe cooled in liquid nitrogen on the anterior wall of the left 
are performed annually in the U.S. alone. Bypass surgery may 60 ventricle for about 20 minutes (R. C. Chin et al., Ann. Thorac. 
be needed for various reasons, for example, to restore blood 
	
Surg. 1995, 60: 12-18). Infarction can be induced by ligation 
flow to cardiac tissue that has been deprived of blood because 	 of the left main coronary artery (Q. Li et al., J. Clin. Invest. 
of a coronary artery disease, or in the case of an angioplasty 	 1997, 100: 1991-1999). 
that did not sufficiently widen the blood vessel, or because of 
	
Cardiac muscle constructs can be implanted within an ani- 
blockages that cannot be reached by, or are too long or stiff 65 mal model at the site of injury. Suitability of the treatment 
for, angioplasty. In conventional coronary artery bypass graft 	 may be determined by assessing the degree of cardiac recu- 
operation, a piece of vein taken from the leg of the patient, or 	 peration that follows the implantation. Cardiac function may 
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be monitored by determining such parameters as left ven- 	 Sankar et al., J. Clin. Invest. 1996, 97: 1436-1446; M. Kita- 
tricular end-diastolic pressure, developed pressure, rate of 	 mura et al., Am. J. Physiol. 1996, 270(4 Pt 2): F614-F622). 
pressure rise, and rate of pressure decay. After a certain period 
	
Thus, while cultured cells may be adequate for some appli- 
of implantation, tissues may be harvested and studied by 	 cations, for example in drug metabolism and detection of 
histology. Cells of the tissue harvested may be tested for their 5 toxins, they fail for others. Bioartificial tissues (especially 
ability to survive and maintain their phenotype in vivo. The 	 human tissue equivalents) that are able to mimic the physi- 
presence and phenotype of the cells can be assessed by immu- 	 ological responses of intact organs, therefore appear as more 
nohistochemistry or ELISA using specific antibody, or by 	 relevant model systems for in vitro research and drug testing. 
RT-PCR analysis. 	 Accordingly, the present invention provides methods of 
Other types of constructs such as bioartificial equivalents io using the inventive tissue-engineered constructs under in 
of striated skeletal muscle tissue, smooth muscle tissue, bone, 	 vitro conditions. These methods comprise producing a three- 
vasculature, or nerve tissue produced by the preparative 	 dimensional construct according to the inventive methods of 
methods of the invention may also be used in a large range of 	 preparation described above; exposing the construct to a test 
clinical applications. 	 factor; and observing the response of the construct to the test 
For example, nerve injuries have a significant impact on the 15 factor. 
quality of life. In the United States, an estimated 235,000 
	
Exposing the construct to a test factor may include submit- 
individuals suffer from physically debilitating spinal cord 	 ting the construct to a mechanical stimulus or to an electrical 
injuries, with total associated costs of more than $350 billion. 	 stimulus. Alternatively, exposing the construct to a test factor 
Peripheral nerve injuries, such as facial paralysis and nerve 	 may include submitting the construct to an experimental pro- 
damage in limbs resulting from accidents, occur even more mo tocol, such as sample preparation by homogenization, fixa- 
frequently than spinal cord injury. Peripheral nerve injury can 	 tion, dehydration, sectioning, washing, incubation, staining, 
result from mechanical, thermal, chemical, or pathological 
	
immuno-staining, and the like. Exposing the construct to a 
causes and may lead to loss of muscle function or to sensory 	 test factor may include submitting the construct to a certain 
loss and phantom sensations. In the treatment of peripheral 	 temperature, pH, gas content or oxygen concentration, or 
nerve damage, surgeons use a nerve graft from the patient, but 25 contacting the construct with an inorganic molecule, an 
regeneration is often incomplete, and, inevitably some irre- 	 organic molecule, a biologically active agent (such as those 
versible damage occurs. Additional disadvantages include 	 listed above), a plant extract, a drug or a potential therapeutic 
loss of function at the donor site and the need for multiple 	 candidate. 
surgeries, which increase risk and cost to the patient. Nerve 	 Observing the response of the construct to the test factor 
defect or damage may be treated by replacing the damaged 30 may be done by studying or assessing any property of the 
tissue with inventive nerve tissue constructs, and submitting 	 construct at the macroscopic (i.e., tissue) and/or at the cellular 
the implanted construct to a biomimetic electrical stimulation 	 level; or by evaluating or determining a change in any prop- 
to enhance its integration with the host tissues and/or to 	 erty of the construct. Exemplary properties of the construct 
maximize cell survival and/or cell functionality in vivo. 	 that can be investigated are strength, elasticity, durability, 
IV. Inventive Constructs as in Vitro Tissue-Equivalents 	 35 conductivity, contractility, tissue organization, cellular orga- 
In addition to their use as advanced bioartificial substitutes 	 nization, cell viability, cell morphology, metabolic activity, 
for in vivo implantation, or to remodel and regenerate tissue 	 cell cycle progression, fraction of apoptotic cells, ultrastruc- 
for the purpose of repairing, replacing, maintaining, or 	 tural features, electrical signal propagation, gene expression, 
enhancing organ function, three-dimensional tissue-engi- 	 and protein expression. 
neered constructs also have important in vitro applications. 40 	 Depending on the response of the construct to be observed, 
Bioartificial tissue equivalents can be useful, for example, as 	 different methods may be used to assess the property of 
biosensors, as model systems for fundamental research stud- 	 interest. Such methods are well-known to those skilled in the 
ies and education, as well as in drug research and develop- 	 art. For example, the construct may be attached to at least one 
ment, including for toxicity and pharmacological testing of 	 strain gauge, and the response of the construct measured as a 
existing drugs, screening of potential therapeutic candidates, 45 change in the strain. A dye may also be added to the construct 
and identification and validation of new targets. 	 and the response of the construct to the test factor observed 
Inventive three-dimensional tissue-engineered constructs 	 using a detection instrument sensitive to the dye. For 
with structural and functional characteristics of a native tissue 	 example, the dye may be selected to reveal the general struc- 
exhibit several advantageous properties over conventional 	 ture of the construct. Additionally or alternatively, the dye 
model systems such as animals and cell cultures. Due to 50 may be selected to specifically stain a specific structural fea- 
differences between species, animal models are not always 	 ture or component of the engineered construct in order to 
adequate representations of human biology. This often pre- 	 reveal the presence or allow the quantification of that particu- 
cludes the extrapolation of observations made in animal stud- 	 lar feature or component. Examples of detection instruments 
ies to the corresponding situation in humans. In addition, the 	 sensitive to dyes include spectrophotometer, spectrofluorom- 
relevance of in vivo controls is often limited due to differ-  55 eter, confocal laser scanning microscope, and the like. 
ences between animals of the same species. Similarly, cell 
	
Particularly interesting is the use of the inventive three- 
cultures are far from being ideal model systems. Cells placed 
	
dimensional tissue-engineered constructs as cell culture sys- 
in culture adopt a two-dimensional monolayer configuration 	 tems with suitable mimicry for in vitro analysis and testing of 
that is different from the organization of cells within a native 	 drugs and/or screening of potential therapeutic candidates. In 
tissue. This generally leads to a loss of at least some key 6o addition to offering the advantage of investigating the effects 
physiological functions and activities that the cells normally 	 of drugs in the context of the native tissue, the inventive 
have as part of an organized tissue in the body. It is known that 	 methods of preparation also allow the production of multiple 
dimensional interactions among various cells, as well as 	 tissue-equivalent materials from a single donor organ, which 
interactions between cells and their external environment, 	 eliminates, or significantly reduces, the problems of controls 
affect physiological functions in a variety of systems (see, for 65 and sample differences. 
example, M. Marx et al., J. Clin. Invest. 1994, 93: 131-139; E. 	 Drugs that are targeted to a specific tissue in the body may 
L. Huguet et al., J. Biol. Chem. 1995, 270: 12851-12856; S. 	 be tested using a corresponding inventive tissue equivalent to 
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determine their safety, efficacy and mechanism of action by 	 exemplary method of cultivating cell-seeded constructs in 
studying their effects on different properties of the tissue 	 perfusion. Example 12 describes an exemplary method of 
construct. For example, the effects of modulators or potential 	 applying the techniques of the invention to mesenchymal 
modulators of contractile activity may be studied using tis- 	 stem cells. 
sue-engineered cardiac muscle tissue. Drugs may be tested 5 
for their effects on tissue maintenance and/or repair. It may 	 Example 1 
also be desirable to use bioartificial cardiac muscle tissue to 
verify the safety and arrhythmogenic potential of drugs that 	 Preparation of Bioartiflcial Cardiac Muscle Tissue 
are not targeted to the cardiovascular system but may produce 
unwanted side effects. 	 10 	 Cardiac Myocyte Preparation. Primary cultures of cardiac 
Any change in the properties of the tissue construct (for 	 myocytes were prepared by enzymatic digestion of ventricles 
example, in tissue organization, contractile activity, electro- 	 obtained from neonatal (2 day old) Sprague-Dawley rats 
physiology, cell organization, cell viability, cell survival, cell 
	 (Taconic), as previously described (M. Toraason et al., Toxi- 
morphology, metabolic activity, expression of certain mark- 	 cology, 1989, 56: 107-113, the contents of which are incor- 
ers and receptors, etc.) that is attributable to the drug or 15 porated herein by reference). Briefly, ventricles (n=50, 5 lit- 
potential therapeutic candidate (compared with untreated tis- 	 ters in 3 independent studies) were incubated with 0.1% 
sue constructs or tissue constructs treated with an inert com- 	 trypsin overnight and dissociated in four to five sequential 
pound) is identified. The effect of the drug or therapeutic 	 steps using 0.1% collagenase. 
candidate is then correlated with the observed change. 	 Cell-Seeded Construct Preparation. Isolated cardiac myo- 
Studying three-dimensional inventive constructs with 20 cytes were suspended in MatrigelO (10 6 cells/5 µL) and 
structural and functional characteristics of a native tissue can 	 seeded onto UltrafoamTM collagen sponge scaffold (6x8xl .5 
also help expand the understanding of the organ biology. This 	 mm) at the density of 0.8x10" cells/cm 3 . 
is particularly true in the case of the heart, which is a difficult 	 Cultivation of Cell-Seeded Construct. After 3 days of cul- 
and complex organ to investigate. Surgical intervention in a 	 tivation, the engineered tissue was transferred to a chamber 
living animal with a defective heart often leads to a shut-down 25 consisting of a 100 mm glass Petri dish fitted with two 1/4 " 
of most of the other critical systems, such as the lungs and 
	
diameter carbon rods (stimulating electrodes) connected to a 
kidneys, which is generally followed by death of the animal. 	 commercial cardiac stimulator (Nihon Kohden) via platinum 
Furthermore, cell-cell and cell-matrix interactions are more 	 wires (as presented in FIG. 2). Silicone tubing spacers were 
readily observed in tissue equivalents than in the less control- 	 used to create six wells between the two electrodes, enabling 
lable, more complex intact organs. Using the inventive prepa-  30 the cultivation of six constructs per Petri dish. Engineered 
ration methods, the initial proportion and type of cells and 	 tissue was stimulated with square pulses, 2 ms duration, at 60 
matrix constituents in a construct can be independently var- 	 beats per minute (bpm) and 5 V for 5 days. The stimulation 
ied. Although cells secrete extracellular matrix components 	 voltage was adjusted to be the minimal required to induce 
during tissue development, these are relatively insignificant at 	 synchronous contractions (observable with optical micro- 
early stages and may become more important later. This sim-  35 scope at IOx magnification) of the engineered tissue. Engi- 
plification of tissue composition allows for a more informa- 	 neered tissue placed in an identical chamber but without 
tive characterization of the properties of the cells and matrix 	 electrical stimulation served as control. All chambers were 
in the tissue and in comparison with the same constituents in 	 orbitally mixed at 25 rpm. All experiments were performed in 
isolation. Building up the complexity of composition of the 	 a 37° C.15% CO 2 humidified incubator. The culture medium 
tissue can then reveal the functions of the specific constituents 40 was Dulbecco's Modified Eagle Medium (DMEM) contain- 
added. The flexibility offered by the preparative methods 	 ing 4.5 g/L of glucose supplemented with 10% Fetal Bovine 
allows the study of cardiac tissue equivalents at different 	 Serum, 10 mM HEPES, 2 mM L-glutamine and 100 units/mL 
stages of development which could dramatically expand our 	 penicillin. 
understanding of cardiac cell biology, cardiac physiology, 	 In the following examples, heart ventricles were used for 
and the relationships between cardiac function and structure 45 comparison purposes whenever necessary. Heart ventricles 
during embryogenesis and cardiac remodeling. In particular, 	 were obtained from 2-day old rats following decapitation. For 
valuable information regarding the differentiation of early 	 biochemical and histological assessments, small pieces of the 
human cardiac precursor cells, the development of excitabil- 	 ventricles (7-13 mg wet wt) were used. For electrophysiologi- 
ity, excitation-contraction coupling, and the molecular sig- 	 cal studies, full-thickness pieces of the ventricular wall (-6x4 
nals involved in these processes could be obtained. 	 50 MM2 , 1.5-2.5 mm thick) were prepared by bisecting heart 
ventricles. The properties of the ventricles were compared 
EXAMPLES 	 with those of the inventive cardiac muscle constructs without 
a priori assumption that the engineered product resembled the 
The following examples describe modes of making and 	 native ventricular tissues. 
practicing the present invention. However, it should be under-  55 
stood that these examples are for illustrative purposes only 	 Example 2 
and are not meant to limit the scope of the invention. 
In particular, the following examples illustrate the prepa- 	 Histological and Immunohistochemical Assessments 
ration of cardiac muscle tissue using the inventive methods 
(Example 1), and describe various analytical experiments 60 	 General Evaluation. Cardiac muscle constructs obtained as 
(Examples 2 to 9) that can be carried out (a) to demonstrate 	 described in Example 1 in the presence or in the absence of 
the cardiac-specific features of the constructs produced, (b) to 	 electrical stimulation were rinsed in PBS, and immersed in 
evaluate construct structure, and (c) to assess their electro- 	 10% neutral buffered formalin (Sigma-Aldrich). Samples 
physiological and contractile properties on a macroscopic 	 were embedded in paraffin, sectioned at 5 µm, and stained 
(i.e., tissue) level as well as on a cellular level. Example 10 65 with hematoxylin and eosin (H+E) for general evaluation. 
describes a method of cardiac differentiation of embryonic 	 Tissue Architecture and Cell Distribution. Staining for car- 
stem cells by electrical stimulation. Example 11 describes an 	 diac troponin I, sarcomeric a-actin, a-myosin heavy chain 
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(a-MHC), (3-myosin heavy chain ((3-MHC) (myocyte-spe- 	 H. Hoyt et al., Circ. Res. 1989, 64: 563-574; M. J. A. Van 
cific contractile proteins) and connexin-43 (Cx-43, gap junc- 	 Kempen et al., Cardiovasc. Res. 1996, 32: 2195-2200). Gap 
tional protein) was used to assess the fraction and distribution 	 junctions may be assessed by immunostaining Cx43, a gap 
of cardiac myocytes in the constructs. 	 junction protein. 
For immunohistochemical staining, cardiac tissue sections 5 
were depariffinized and antigen was retrieved by heat treat- 	 Example 3 
ment for 20 minutes at 95° C. in decloaking chamber (Biocare 
Medical). Subsequently, endogenous peroxidase activity was 	 Biochemical and Molecular Assays 
quenched by incubation in 0.3% hydrogen peroxide for 30 
minutes at room temperature (RT), the sections were then 10 DNA and Protein Assays. Samples for DNA, total protein, 
blocked with 10% horse serum for 30 minutes at RT, then 	 and Western blot analyses are homogenized in buffer (1 M 
incubated for 1 hour at 37° C. with mouse anti-cardiac tropo- 	 NH4OH/2% Triton X-100, 0.04 mL/mg wet wt of sample) for 
nin I (Biodesign) and mouse anti-sarcomeric a-actin mono- 	 1 minute. DNA is measured fluorimetrically by Hoeschtbind- 
clonal (Sigma) antibodies diluted 1:150 and 1:500, respec- 	 ing, and total protein is measured by a commercially available 
tively in PBS containing 0.5% Tween 20 and 1.5% horse 15 kit (Bio-Rad) as previously described (N. Bursac et al., Am. J. 
serum. Subsequently, sections were incubated for 30 minutes 	 Physiol. Heart Circ. Physiol. 1999, 277: H433-H444; R. L. 
at RT with a secondary antibody (horse anti-mouse IgG, 	 Carrier et al., Biotechnol. Bioeng. 1999, 64: 580-589). 
Standard Elite ABS lit, Vector Laboratories), diluted 1:200, 	 Protein Analysis. The protein expression levels of creatine 
and then with an avidin-biotin complex agent for 30 minutes 	 kinase-MM (CK-MM) and myosin heavy chain (MHC), 
at RT and 3,3'-diaminobenzidine (Sigma) for 15 minutes at 20 troponin I and connexin-43 in constructs are quantified as 
RT. A humidified chamber was used for all incubation steps. 	 markers of cellular differentiation. Creatine kinase, a dimer of 
Sections were counterstained with Harris hemotoxylin 	 M- or B-type subunits, plays a vital role in the maintenance of 
(Sigma-Aldrich) and coverslipped using xylene-based 	 cytosolic ATP (L. H. Opie, The HeartPhysiologyfrom Cell to 
mounting media (Cytoseal). Neonatal rat heart and bovine 	 Circulation, L. Opie (Ed.), Lippincott-Raven: Philadelphia, 
tendon served as positive and negative controls, respectively. 25 1998, pp. 295-342), whereas MHC is involved in the genera- 
Construct architecture was assessed from stained tissue sec- 	 tion of contractile force (L. H. Opie, The Heart Physiology 
tions using videomicroscopy and Scion Image software. 	 from Cell to Circulation, L. Opie (Ed.), Lippincott-Raven: 
For immunofluorescence, sections were depariffinized and 
	
Philadelphia, 1998, pp. 295-342). During cardiac tissue 
antigen was retrieved by heat treatment for 20 minutes at 95° 
	
development and differentiation, the muscle-specific 
C. in decloaking chamber (Biocare Medical), blocked with 30 CK-MM isoenzyme (J. S. Ingwall, Biochem. Soc. Trans. 
10% horse serum for 40 minutes at RT, then incubated for 1 
	
1991, 19: 1006-1010; H. Ueno et al., J. Cell Biol. 1988, 107: 
hour at 37° C. with primary antibodies: mouse anti-a-myosin 	 1911-1918) and the contractile protein MHC (B. Goldman et 
heavy chain (hybridoma supernatant, ATCC, full strength), 	 al., Exp. Cell Res. 1996, 228: 237-245) are significantly 
mouse anti-p-myosin heavy chain (Chemicon, full strength) 	 upregulated. The phosphorylation state of Cx43 (determined 
and rabbit anti-Connexin-43 (Chemicon, 1:50) diluted in 35 by collapsing of the 43-kDa band into a 41-kDa band after 
PBS containing 0.5% Tween 20 and 1.5% horse serum. Sub- 	 alkaline phosphatase treatment), is an indication that the gap 
sequently, the constructs were incubated with the following 	 junctions that are formed during construct cultivation are 
secondary antibodies (all from Vector Laboratories) for 30 	 functional (A. P. Moreno et al., Circ. Res. 1994, 74: 1050- 
minutes at 37° C.: Texas Red conjugated horse anti-mouse 	 1057). 
IgG (1:100) fora-MHC visualization, fluorescein conjugated 40 	 To quantify the relative expression levels of Cx43, MHC, 
anti-mouse IgG (1:100) for R -MHC visualization, and fluo- 	 and CK-MM, the constructs are frozen in liquid nitrogen 
rescein conjugated goat anti-rabbit IgG (1:200) for Cx-43 	 immediately after the end of the cultivation. Proteins are 
visualization. The sections were counterstained with DAPI 	 extracted using ammonium hydroxide extraction buffer (con- 
and coverslipped (Vectorshield mounting medium with 	 taining 1 M NH4OH, 0.2% Triton X-100) from the scaffolds 
DAPI). Neonatal rat ventricles and bovine articulate cartilage 45 by steel-ball bead beater. After centrifugation for 10 minutes 
served as positive control and negative control, respectively. 	 at 12,000 g at 4° C., the homogenates are stored at —80° C. for 
Construct architecture and cell distribution were assessed 
	
further analysis. On the day of the analysis, homogenates are 
from stained tissue sections using a fluorescent microscope 	 diluted (1 part sample to 2 parts buffer) in Laemni buffer 
(Axioplan, Zeiss) and Open Lab software. 	 (Bio-Rad) containing 5% mercaptoethanol and 2% SDS and 
Constructs cultivated in the presence of electrical stimula-  5o boiled for 5 minutes to denature proteins. Homogenates con- 
tion exhibited aligned nuclei and thick aligned myofibers 	 taining 20 µg of total protein each are separated on 12% 
expressing cardiac troponin I and sarcomeric a-actin. In con- 	 Tris-glycine minigels (Bio-Rad) using kaleidoscope 
trast, non-electrically stimulated constructs mostly contained 	 prestained standards (Bio-Rad) at a constant voltage of 100 V 
round, mononucleated cells with lower level of differentia- 	 for 2 hours at room temperature. Three independent con- 
tion (see FIG. 3). Due to the cultivation in an orbitally mixed 55 structs from each group are analyzed to compare the expres- 
dish, both groups had cells confined to the —200 µm thick 	 sion of the protein bands, and each lane is loaded with the 
surface layer. 	 same protein concentration (20 µg). 
Cardiac Gap Junctions Assessment. Cardiac gap junctions 	 Eluted proteins are electroblotted in 1 x Tris/Glycine/SDS 
are membrane specializations that permit the passage of ions 	 running buffer (Bio-Rad) onto polyvinylidene difluoride 
and small signaling molecules between myocytes, thus facili-  60 membranes (Bio-Rad) at 100 V for 60 minutes at room tem- 
tating electrical conduction and chemical communications 	 perature in a Bio-Rad Trans-Blot cell. Blots are first incubated 
(E. Page and C. K. Manjunath, The Heart and the Cardiovas- 	 with 5% nonfat dry milk at room temperature for 1 hour in 
cular System, H. Fozzard et al. (Eds.), Raven: N.Y., 1986, pp. 	 PBS-T to block non-specific binding of antibodies and then, 
573-600). The size and spatial distribution of myocyte gap 	 for an additional 1-2 hours, with the appropriate primary 
junctions changes during development from a punctuate dis-  65 antibody. The primary antibodies are: (1) rabbit anti-Cx43 
tribution over the entire cell membrane in neonates to a con- 	 (Chemicon), diluted 1:10 in PBS-T; (2) goat anti-CK-MM 
fined distribution at end-to-end cell connections in adults (R. 	 (Biodesign), diluted 1:3,000 in PBS-T; (3) mouse anti-tropo- 
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nin I (Biodesign), diluted 1:3,000 in PBS-T; (4) mouse anti-
a-MHC (ATCC) hybridoma supernatant; and (5) mouse anti-
R -MHC (Chemicon), diluted 1:50 in PBS-T. Blots are washed 
five times with PBS-T and incubated 1 hour at room tempera-
ture with rabbit anti-goat, rabbit anti-mouse, or sheep anti-
rabbit IgG antibodies (Sigma), respectively, all conjugated to 
horseradish peroxidase and diluted 1:10,000 in PBS-T. After 
five additional washes, the immunocomplexes are developed 
using enhanced horseradish peroxidase-luminol chemilumi-
nescence (ECL Western blotting detection reagents, Amer-
sham) and detected after exposure to photographic film (Hy-
perfilm-ECL) for 5-30 seconds. Band intensity is quantified 
by an image analysis software (Scion Image). FIG. 4A is a 
photograph of the protein bands, showing that the intensity of 
the protein bands from stimulated constructs is greater than 
that from non-stimulated constructs. The ratio of a-MHC to 
R -MHC after  days (pre-stimulation) was 1.5. For stimulated 
constructs, the ratio was 1.8 after 5 days, while the ratio was 
1.4 for non-stimulated control constructs. 
Gene Expression. Total RNA from the constructs is 
extracted using Trizol reagent (GibcoBRL) and RNeasy® 
mini kit (Qiagen) following manufacturer's instructions. 
Briefly, constructs in Trizol are shredded by steel-ball bead 
beater using 6 cycles of 25 rpm for 10 seconds each. The 
supernatant is collected after centrifugation at 14,000 rpm for 
15 minutes. Total RNA is collected by RNA column chroma-
tography using water as eluant. RNA concentration is deter-
mined by measuring the absorbance at 260 mn by UV spec-
trophotometry. 
RT-PCR. One step RT-PCR is carried out as described 
(Qiagen). Total RNA (0.5-0.05 µg) is used with specific prim-
ers and the RT-PCR reactions are performed at 50° C. for 30 
minutes, 95° C for 15 minutes, 23 cycles at 94 0 C. for 1 
minute, 60° C. for 1 minute, 72° C. for 1.5 minute, and then 
72° C. for 10 minutes. The different primers used in the PCR 
reactions are shown below. 
30 
FIG. 4B is a picture comparing the amount of RNA for the 
above for non-stimulated and stimulated samples. 
Example 4 
5 
Cell Viability Assessment 
To detect viable cells at depths of up to 100 M from the 
construct surfaces, the constructs are extensively washed in 
10 PBS and then incubated with calcein-AM (Molecular 
Probes), a substrate that is hydrolyzed by intracellular 
esterases to a fluorescent product that is retained by cells with 
intact membranes. Intact cells in constructs are visualized 
without further preparation using a confocal laser scanning 
15 microscope (MRC-500, Bio-Rad) equipped with an argon-
krypton laser emitting monochromatic light at 488 mu. Opti-
cal sectioning is done using a 20x objective in 1.5-µm steps. 
Individual images are reconstructed into composite images 
(31) reconstruction analysis) using computer software (Bio- 
20 Rad). 
Example 5 
Metabolic Activity Assays 
25 
Metabolic activities of cells within constructs and ventricu-
lar tissues are assessedby theuptake and enzymatic reduction 
of the tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma). Samples (2-15 
30 mg wet wt) are rinsed with PBS and incubated with MEM 
(GIBCO-BRL) without phenol red and 0.5 mg/mL MTT for 
4 hours on an orbital shaker at 37° C. and 60 rpm. Medium is 
replaced with an equal volume of 0.1 M HCl in absolute 
isopropanol and pipetted directly through the constructs to 
35 solubilize the resulting formazan crystals. After 10 minutes of 
incubation at 37° C., the absorbance is read at 570 mu, using 
a microplate spectrophotometer. 
Forward a-MHC: 
5 1 -GGAAGAGCGAGCGGCGCATCAAGG-3' 
Reverse a-MHC: 
5 1 -CTGCTGGACAGGTTATTCCTCA-3' 
Forward P -MHC: 
5 1 -GCCAACACCAACCTGTCCAAGTTC-3' 
Reverse P -MHC: 
5 1 -TCAAAGGCTCCAGGTCTCAGGGC-3' 
Forward Cx-43: 
5 1 -CATTGGGGGGAAGGCGTGAGG-3' 
Reverse Cx-43: 
5 1 -AGCGCACGTGAGAGATGGGGAAG-3' 
Forward GAPDH: 
5 1 -TGGAAAGCTGTGGCGTGATG-3' 
Reverse GAPDH: 
5 1 -TCCACCACCCTGTTGCTGTAGC-3' 
Forward integrin fp: 
5 1 -GCAGCAGCATCTTAGTCACAGTAGG-3' 
Reverse integrin fp: 
5 1 -TTTGATTCTGTTTAACTAGTCCTGG-3' 
Forward cardiac actin: 
5 1 -CAGATCTTCTCCATGTCG-3' 
Reverse cardiac actin: 
5 1 -GGCTGGCTTTGCGGGTGA-3' 
Example 6 
40 
Media Analysis 
Physiological ranges of P02 (115-130 mmHg), PCO 2 (48-
55 mmHg), and pH (7.21-7.33) are maintained for the dura- 
45 tion of cultivation, as measured by a blood gas analyzer (IL 
1610, Instrumentation Laboratory). Glucose and lactate con-
centrations are measured using a glucose/lactate analyzer 
(2300 StatPlus, YSI). The activity of LDH in the culture 
media is monitored using a LDH-L reagent kit (Chiron Diag- 
50 nostics). Media samples are sonicated using a Sonic Dismem-
brator (Vibra-Cell, Sonics and Materials), and absorbance is 
measured at 340 nm (Spectronic 1001 +, Milton Roy) against 
cell-free medium. 
55 	 Example 7 
Transmission Electron Microscopy 
Samples are fixed in Kamovsky's reagent (0.1 M sodium 
60 cacodylate with 2% paraformaldehyde and 2.5% gluteralde- 
hyde, pH=7.4), post-fixed in 1% osmium tetroxide in veronal- 
acetate buffer, dehydrated in graded ethanol in propylene 
oxide, and embedded in Epon 812 (Polysciences). Sections 
(70 mn thick) are prepared using a Leica Ultra Cut and a 
65 diamond knife, stained with lead citrate and uranyl acetate, 
and examined using a Philips EM410 transmission electron 
microscope operated at 80 kV. FIG. 5 is a series of transmis- 
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sion electron micrographs illustrating that stimulated tissue 
constructs (FIG. 513) is more similar morphologically to 
native tissue (FIG. 5A) than are non-stimulated tissue con-
structs (FIG. 5C). 
Example 8 
Electrophysiological Assessment 
An electrophysiological system was custom-designed to 
enable stimulation and recording of unipolar extracellular 
potentials in constructs and ventricular tissues under con-
trolled environmental conditions using a linear array of elec-
trodes. A cylindrical Plexiglas is tightly fitted inside an elec-
trically grounded brass casing placed on a 37° C. heater 
(VWR). The brass case distributes the heat evenly through the 
chamber and serves as an electrostatic shield. The chamber is 
gassed with a prewarmed mixture of 5% CO z in air and filled 
with 50 mL of culture medium (DMEM with 15 mM HEPES, 
4.5 g/L glucose), which is recirculated (at 60 mL/minute for 
constructs and 120 mL/minute for ventricular tissues) using a 
pulseless gear pump (Cole-Palmer). Temperature and pH are 
maintained at 37.0±0.1 ° C. and 7.32±0.02, respectively. 
All microelectrodes are made of insulated tungsten wire 
and have uninsulated tips with diameters of 50±6 µm (Micro-
probe). Two electrodes for bipolar stimulation are positioned 
200 µm apart and connected to a programmable cardiac 
stimulator (SEC-3102, Nihon Kohden). Eight recording elec-
trodes are positioned 500 µm apart in a linear array, 1.5 to 5 
mm from the stimulating site. Exact distances between elec-
trodes are measured using a microscope and NIH 1.60 image 
analysis software. Shielded cables connect recording elec-
trodes to bioelectric amplifiers (AB.601 G, Nihon Kohden). A 
referenceAg AgCl electrode (WPI)is placed in the medium 
3.5 away from the microelectrode. 
Samples are placed in a tissue holder 2-3 mm under the 
surface of the culture medium, secured using Teflon screws, 
and left to equilibrate for 15 minutes. An XYZ mechanical 
micropositioner (Taurusr, WPI) is used to gradually advance 
the microelectrode away toward either the top surface of the 
construct or the epicardial surface of the ventricle, and pacing 
impulses are simultaneously applied (3-5 V, 1-ms pulses at a 
rate of 60 beats/minute). The position of the array is fixed at 
the point where the amplitudes of the recorded responses 
appear maximal, and a recording protocol is performed as 
follows. 
Spontaneous beating, if present, is recorded for 3-5 min-
utes. After 15 minutes, monophasic pacing pulses (1-ms dura-
tion) are applied at a rate of 60 beats/minutes, starting at a 
pacing voltage of 0.1 V, which is then increased in 0.1 V 
increments until the sample is captured (i.e., until each pacing 
impulse is followed by a recorded tissue response). The cor-
responding pacing voltage, defined as the excitation thresh-
old, represents the lowest stimulus that produces a stable 
propagation (for at least 1 minute at a rate of 60 beats per 
minute) over the length of the recording array. For the next 
20-30 minutes, the sample is continuously paced at a rate of 
60 beats per minute using pacing amplitudes 1.5 times higher 
than the excitation threshold, and responses are recorded 
every 4-5 minutes for a period of 1 minute. The pacing rate is 
then increased every 5 minutes by 30 beats per minute, and 
responses to each rate are recorded for the last 40 seconds. 
The maximum pacing frequency at which the sample can be 
captured for at least 5 minutes is defined as the maximum 
capacity rate. After reaching the maximum capacity rate, 
stimulation is stopped for 10 minutes and then reapplied at 30 
and 60 beats per minute for 5 minutes each to check for 
32 
reproducibility of the recorded waveforms. At the end of the 
experiment, double and triple extra-stimuli and rapid stimu-
lation at frequencies above the maximum capture rate are 
applied in an attempt to induce arrhythmia. 
5 	 All recorded signals are amplified and band-pass filtered 
between 0.3 and 1,000 Hz. The unfiltered noise level is 35 µV, 
peak to peak, with virtually no 60-Hz component. Analog 
recordings are digitized at a sampling rate of 3 kHz using a 
16-bit analog-to-digital board (AT-MIO-16X, National 
10 Instruments), real-time displayed using LabView data acqui-
sition software, and stored and analyzed using MATLAB 
(The Mathworks). 
Activation times at each recording electrode are deter- 
15 mined as the minima of five-point derivatives of the low-pass 
filtered signals. The stimulus-activation time intervals at each 
electrode (conduction times) are plotted against the corre-
sponding distances and fitted by linear regression. The con-
duction velocity of a propagated beat is calculated as the 
20 inverse slope of the best linear fit. The peak-to-peak (p-p) 
amplitudes of the responses are determined from linearly 
detrended signals around the activation times. Recording 
sites with very low or fractioned (polyphasic) activity are 
ignored. 
25 	 For each tissue sample, p-p amplitudes at each electrode 
and conduction velocities are averaged from recording made 
during the initial 20 minutes of pacing at 60 beats per minute 
(i.e., over at least 200 beats). Conduction velocity, maximum 
amplitude, and average amplitude are calculated, respec- 
30 tively, as the averages of conduction velocities, maximum p-p 
amplitudes, and all p-p amplitudes from all samples within a 
group. The maximum and average amplitudes, respectively, 
represent local and spatially averaged properties of constructs 
35 or ventricles. 
Example 9 
Evaluation of Contractile Response 
40 
The contractile function of engineered cardiac constructs is 
evaluated by monitoring and videorecording contractile 
activity upon electrical stimulation at IOx magnification 
using a microscope (Nikon Diaphot). Each construct is placed 
45 in a 100 mm Petri dish containing 120 mL Tyrode's solution 
(140 mM NaCl, 5.4 mM KCl, 0.33 mM NaH 2PO41  1.8 mM 
CaC1 21  1 mM MgCl2,  5 mM HEPES, 5.5 mM D-Glucose, pH 
7.4) between two custom made electrodes (carbon rods) con-
nected to a cardiac stimulator (Nihon Kohden). The tempera- 
50 ture is maintained at 37° C. using a heating tape (VWR) 
attached to the bottom of the Petri dish. The stimuli (square 
pulses, 2 ms duration) are applied at a rate of 60 bpm starting 
at an amplitude of 1 V that is gradually increased at incre-
ments of 0.1 V until the excitation threshold (ET) is reached 
55 and the entire construct is observed to beat synchronously. 
The maximum capture rate (MCR) is defined as the maxi-
mum pacing frequency for a synchronous stimulus-response 
of the constructs. To measure MCR, the stimulation fre-
quency is increased from 60 to about 600 bpm with a mini- 
60 mum step size of 10 bpm, at a constant voltage that is equal to 
either 150% or 200% of the excitation threshold until the 
construct contractions become asynchronous or irregular or 
completely ceased. For evaluation of contraction amplitude, 
video recorded beating sequences (1-5 minutes) are digitized 
65 at the rate of 30 frames per second. The "face-sectional" area 
of each construct is determined as a function of time using 
image analysis software (Scion Image). Amplitude of con- 
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34 
traction is expressed as fractional area change. FIG. 6 illus- 	 medium directly through the construct. Each seeding loop 
trates the increase in the fractional area of stimulated samples 	 containing one perfused cartridge was placed onto a push/pull 
over time. 	 syringe pump as shown in FIG. 1A. 
Each cartridge was connected to two 80-cm-long coils of 
Example 10 	 5 1.6 mm ID, 3.2-mm OD platinum-cured silicone tubing serv- 
ing as gas exchangers, and two 1 0-mL syringes serving as 
Cardiac Differentiation of Embryonic Stem Cells by 	 medium reservoirs, sampling ports, and for de-bubbling. Car- 
Electrical Stimulation 	 tridges were completely filled with culture medium, with the 
use of a pair of 3-mL syringes, one full and one empty, 
Embryonic stem cells are grown using previously estab-  io connected to the circuit at the inlet and outlet of the cartridge 
lished approaches such as those described by Itskowitz-Eldor 	 via 3-way stopcocks. The total volume of medium in the 
et al. (Mol. Med. 2000, 6: 88-95). The cells are grown in 	 cartridge, tubing, and reservoir syringes was 8 mL (1.5 mL in 
monolayers in DMEM medium containing 20% FBS, in a 	 the cartridge, 4 mL in the tubing, 2.5 mL in one syringe, and 
humidified 5% CO2/air 37° C. environment. Cells are pas- 	 the other syringe was empty). Any air bubbles were displaced 
saged every 6 or 7 days after 70% confluence is reached. After 15 by culture medium injected from the de-bubbling syringe 38a 
each passage, adherent cells are detached by trypsin diges- 	 into the downstream syringe 38b. The seeding set-up was 
tion, and the cell number and viability are assessed. 	 placed in a 37° C.15% CO z incubator, and the pump was 
Cells are then prepared in form of a cell suspension in 	 programmed to the set flow rate, with the reversal of flow 
Matrigel (10 6 cells/5 µL Matrigel) as described above for 	 direction after 2.5 mL was perfused in a given direction. All 
cardiac myocytes. The Matrigel suspension is seeded onto a 20 components (cartridges, screens, gaskets, tubing) were steam 
UltrafoamTM collagen sponge scaffold (6x8xl.5 mm), which 	 sterilized for 30 min. Cartridges were subj ected to alternating 
was first hydrated in culture medium (DMEM) for 2 hours 	 flow perfusion for the first 1.5 hours to prevent washout of 
and blotted dry. The cell-Matrigel mixture is loaded to the 	 cardiomyocytes before they attached to the scaffold and then 
scaffold, at the initial cell density of 8x10' cells/mL scaffold 
	
to unidirectional perfusion for an additional 7 days (FIG. 113). 
volume (using 60 µL of cell-Matrigel suspension per scaf-  25 	 The unidirectional perfusion apparatus included one chan- 
fold). 	 nel of a multichannel peristaltic pump 50 (Cole Parmer, Ver- 
The construct is placed into a 6-well plate (one construct 	 non Hills, Ill.), a gas exchanger 52 (a 3 m coil of thin silicone 
per well) and transferred to an incubator (humidified 5% CO z , 	 tubing), a reservoir bag 54, and two syringes 56a and 56b. The 
37° C. environment) for 20 minutes in order for the gel to 	 total volume of medium was 32 mL. The flow rate was set at 
harden. Cardiac differentiation medium (DMEM, 10% FBS, 30 0.5 mL/min, corresponding to an interstitial velocity of 500 
1 % Pen/Strep, 1 % HEPES) is then added (5 mL per well) and 	 micron/s and maintained throughout the cultivation. The cul- 
the construct is cultured on an orbital shaker at 25 rpm for 3 
	
ture medium was DMEM (4.5g/L glucose) supplemented 
days. On Day 4, the construct is transferred into the stimula- 	 with 10% FBS, 10 mM HEPES, 2 mM L-glutamine, and 100 
tion chamber (a culture chamber equipped with the stimula- 	 U/mL penicillin (all from GIBCO-BRL). Control constructs 
tion electrodes, as described above for the cultivation of car-  35 were cultivated in orbitally mixed dishes (25 rpm). 
diac myocytes). The electrical stimulation is applied for 7-8 	 Analytic methods. Constructs and culture medium were 
days at a frequency between 60 and 180 bpm (1-3 Hz) and an 	 sampled immediately postseeding and after 1.5 h, 1 day, and 
amplitude of 5 V. 	 7 days of culture. Cell number, viability, metabolism [lactate 
Cardiac differentiation is assessed on-line, without inter- 	 yield on glucose (L/G)], and cell cycle were assessed at all 
rupting the cultivation, by measuring the contractile 40 time points; cell distribution, the presence of contractile pro- 
responses (contractile amplitude, frequency) as described 	 teins, and contractile function were assessed at 7 days. A total 
above for cardiac myocytes). Tissue constructs are harvested 	 of 26 rat litters (-260 heart ventricles) was used in 10 inde- 
at timed intervals and processed histologically and immuno- 	 pendent experiments, with n=2-8 constructs/data point. 
histochemically for overall evaluation and to assess the pres- 	 Statistical analysis. Individual and interactive effects of 
ence and distribution of cardiac specific markers (H&E stain-  45 culture system and time were determined using two-way 
ing, troponin I, connexin-43, a-MHC, R -MHC). The same 	 ANOVA (SigmaStat). The culture system was investigated at 
markers are determined using immunoblots and RT-PRC. 	 two levels (orbital shaker at 25 rpm; perfusion of 0.5 ml/min); 
Metabolic rates (glucose consumption and lactate produc- 	 the effect of time was investigated at three levels (1.5 h, 1 day, 
tion) and LDH (an indicator of cell damage) are measured 	 and 7 days) with respect to live cell number, cell viability, 
biochemically from medium samples. Total DNA and protein 50 glucose consumption rate, and the molar ratio of lactate pro- 
are measured biochemically in harvested constructs as 	 duced to glucose consumed. For cell cycle fractions, the 
described above for cardiac constructs prepared with cardiac 	 effect of time was investigated at two levels (1 and 7 days). All 
myocytes. Early cardiac progenitor markers (MEF2-C, 	 experimental data passed normality and equal variance tests. 
Nkx2.5, GATA 4, TEF-1) and cardiac markers expressed later 	 For pairwise comparisons, we chose the most conservative 
during the development (MEF2-A, MEF2-D) are determined 55 Tukey's post hoc test with P<0.05 considered as significant. 
by RT-PCR. 	 Cell number and viability. Cell number and viability were 
assessed using ethidium monoazide bromide (EMA) in con- 
Example 11 
	 junction with fluorescence-activated cell sorting (FACS) as 
previously described (25). In brief, EMA was added to ali- 
Perfusion of Constructs 	 6o quots of freshly isolated neonatal rat cardiomyocytes or con- 
structs (10 ld of 50 µg/ml solution per 1 x10 6 cells suspended 
Gel-cell inoculated scaffolds were placed between two 	 in 100 µl PBS) in six-well dishes that wereplaced on ice under 
stainless steel screens and two silicone gaskets in 1.5-mL 
	
fluorescent light for 10 min to allow for EMA to cross-link to 
polycarbonate perfusion cartridges (one scaffold per car- 	 DNA of nonviable cells. EMA-labeled constructs were 
tridge) (Millipore, Bedford, Mass.). The screens (85% open 65 digested with collagenase and dispase (10 ml of solution 
area) provided mechanical support during perfusion, and the 	 containing 0.6 mg/ml collagenase type II with 282 U/mg and 
gaskets (1 mm thick, 10 mm OD, 5 mm ID) routed the culture 	 1.2 Ural of dispase in culture medium per construct) for 30 
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min at 37° C. and 30 min on ice, with periodic pipetting to 
dissociate cell aggregates. EMA-labeled dissociated cells 
were rinsed with culture medium and counted using a 
hemocytometer (VWR). Cells were resuspended in PBS at 
the concentration of 106 cells/ml and subjected to FACS 
(FACScan, Becton-Dickinson). The change in cell viability 
was calculated as the difference between the measured 
viabilities of freshly isolated cells and cells harvested from 
digested constructs. As an independent measure of cell dam-
age and death, a lactate dehydrogenase (LDH) assay was 
performed on samples of culture medium after 1, 3, and 7 
days of culture using a commercial kit (Chiron Diagnostics; 
East Walpole, Mass.), as described in Example 2. 
Cell survival was consistent with the conditions of flow in 
each experimental group. Flow visualization demonstrated 
that the central 5-mm-diameter region of the perfused con-
structs had uniform interstitial flow, whereas the outer edge 
ring between the two gaskets was shielded from flow (FIG. 
1A). In orbitally mixed dishes used as a control, fluid flow was 
generated at construct surfaces but not in their interiors. 
The effects of culture system and time of culture on cell 
survival and function are shown in FIG. 7; the corresponding 
statistical data are shown in Table 1. In seeded constructs 
(1.5-h time point), the live cell numbers were comparable for 
perfused and control constructs (-7 million cells/construct in 
both groups; FIG. 7A). Throughout the cultivation (1- and 
7-day time points), the number of live cells in perfused con-
structs was significantly higher than that in dish-grown con-
structs (FIG. 7A). Notably, the number of live cells in dish-
grown constructs decreased rapidly during the first day of 
culture and continued to decrease relatively slowly between 
days 1 and 7. In contrast, live cell numbers in perfused con-
structs did not change from 1.5 h to day 1 and decreased 
slowly over the time of culture. The volume fraction of the 
construct that was adequately perfused corresponded roughly 
to the fraction of cells that remained viable over 7 days of 
culture (FIG. 7A). Cell viability was significantly higher in 
perfused than dish-grown constructs at all time points (FIG. 
713). Importantly, the final cell viability in perfused constructs 
(81.6±3.7%; FIG. 713) was not significantly different from the 
viability of the freshly isolated cells (83.8±2.0%), and it was 
markedly and significantly higher than the cell viability in 
dish-grown constructs (47.4±7.8%; FIG. 713). The overall 
level of cell damage and death was assessed by monitoring the 
levels of LDH activity in the culture medium. At all time 
points tested (1, 3, and 7 days), the levels of LDH were 
significantly lower in perfused constructs compared with the 
orbitally mixed dish (FIG. 7E), indicating less cell damage 
and death. 
TABLE 1 
P Values for individual and interactive effects of culture time and 
culture system on cell viability and metabolism 
Live Cell 	 Cell 	 Glucose 
Number Viability 	 L/G Consumption 	 LDH 
Culture time 	 <0.001 	 <0.002 	 <0.001 	 <0.001 	 NS 
Culture 	 <0.001 	 <0.001 	 0.003 	 0.035 	 <0.001 
system 
Culture 	 NS 	 0.035 	 0.038 	 NS 	 NS 
time x 
system 
Values were determined by two-wayANOVA in conjunction with Tulcey's post hoc test. 
P < 0.05 was considered significant. 
L/G, lactate-to-glucose ratio; 
LDH, lactate dehydrogenase, 
NS, not significant 
Cell metabolism. Cell metabolism was assessed from the 
molar ratio of lactate produced to glucose consumed (L/G; 
ideally, 1 mol/mol] for aerobic metabolism and 2 mol/mol for 
anaerobic metabolism). Glucose and lactate concentrations 
were measured in 15 culture medium sampled at timed inter-
vals using a glucose and L-lactate analyzer (model 2300 
5 STAT Plus, Yellow Springs Instruments; Yellow Springs, 
Ohio). 
The Poe in culture medium was significantly higher at the 
inlet of perfusion cartridges than in orbitally mixed dishes 
(145±1 vs. 135±1 mmHg, P<0.05, n=5-8). The measure 
to decrease in oxygen tension across the perfused cartridge was 
only 8 mmHg, suggesting that culture medium rich in oxygen 
was available to the cells throughout the construct volume. In 
contrast, culture medium rich in oxygen was available only to 
the cells at surfaces of dish-grown constructs. The molar ratio 
15 of lactate produced to glucose consumed (L/G) was —1 for 
perfused constructs throughout the duration of culture, indi-
cating aerobic cell metabolism (FIG. 7C). In contrast, L/G 
increased progressively from 1 to —2 with time of culture for 
dish-grown constructs, indicating a transient to anaerobic cell 
20 metabolism. (FIG. 7G). The increase in L/G with time in dish 
cultures was statistically significant (P<0.001). The con-
sumption rate of glucose, the primary energy source in our 
system, per unit live cells was not significantly different 
between the groups at any time point. It decreased after seed- 
25 ing to values that were comparable at 1 and 7 days of culti-
vation and consistent with previously published data (8) 
(FIG. 7D). 
Individual and interactive effects of culture system and 
culture time on cell viability and metabolic function. Impor- 
30 tantly, both the culture system (perfusion or orbital dish) and 
time of culture (1.5 h, 1 day, and 7 days) had statistically 
significant individual effects on the cell survival parameters 
shown in FIG. 7 (live cell number, cell viability, L/G, glucose 
consumption). The culture system alone had a significant 
35 effect on the levels of LDH in culture medium. For cell 
viability and L/G, we detected additional interactive effects of 
culture system and culture time (Table 1). 
Cell cycle analysis. For cell cycle analysis, constructs were 
digested, and cells were pernneabilized in 70% ethanol (1 
40 mi106 cells) for 30 min at 4° C. After centrifugation (10 min, 
1,000 rpm), the pellet was resuspended in a solution of 50 
ltg/ml RNase A and 0.1% Triton X-100 in PBS (0.5 ml/10 6 
cells) to digest double-stranded RNA, which might interfere 
with staining. Propidium iodide was added (50 µg/ml), and 
45 the cell suspension was subjected to FACS (FACScan, Bec-
ton-Dickinson) to determine the fraction of cells in the G o/G,, 
S, and Gz/M phases. Peak deconvolution was performed 
using ModFit LT V2.0 for Macintosh. 
Cell cycle analysis of the mononucleated cell fraction indi- 
50 cated that there was a proliferative cell compartment in both 
perfused and dish-grown constructs (FIG. 8). The relative 
fractions of cells in the G O/G 1 , S, and Gz/M phases deter-
mined for the initial cell population (time 0 in FIGS. 8, A and 
B) were maintained throughout the duration of culture in 
55 perfused but not dish-grown constructs. Cells isolated from 
perfused constructs and freshly isolated cardiomyncytes had 
more cells in the S phase than in the G z/M phase, whereas 
cells isolated from dish-grown constructs appeared unable to 
complete the cell cycle and accumulated in the G z/M phase. 
6o After 7 days of culture, the percentage of cells in the S phase 
was significantly higher in perfused than dish-grown con-
structs (FIG. 8). Statistical analysis demonstrated significant 
effects of culture system on fractions of cells in the S phase 
(P-0.005) and Gz/M phase (P=0.01) and culture time on the 
65 fraction of cells in the G O/G 1 phase (P-0.018). 
Histological evaluation. For histological evaluation, con-
structs were paraffin embedded, bisected, cross sectioned (5 
35 
ET, V 
Before PA 	 1.1 +/— 0.1 	 3.3 +/— 0.2° 	 4.5 +/— 0.4ab 
After PA 	 1.5 +/— 0.1 	 3.5 +/— 0.1° 	 4.4+/— 0.1ab 
MCR at 
40 150% ET, 
beats/min 
Before PA 413+/-7 420+/-30 502+/— 32 
After PA 465 +/— 15 415+/-35 378 +/— 31` 
45 MCR at 
200% ET, 
beats/min 
Before PA 427+/-40 415+/-45 523+/— 14 
After PA 427+/-58 435+/-45 380 +/— 31` 
50 
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µm thick), and either stained with hematoxylin and eosin or 
immunostained as described in Example 2 with monoclonal 
antibodies for sarcomeric a-actin (diluted 1:500, Sigma), 
cardiac troponin I (diluted 1:150, Biodesign), or sarcomeric 
tropomyosin (diluted 1:100, Sigma). 
After 7 days of culture, the overall tissue architecture 
appeared markedly better for perfused than dish-grown con-
structs. The 100- to 200-µm-thick peripheral layers of con-
structs from both groups consisted of tightly packed cells 
containing cardiac differentiation markers in contrast to con-
struct interiors, which were markedly different (FIG. 9). 
Medium perfusion maintained high and spatially uniform cell 
density throughout the construct volume (except in the outer 
edge regions shielded from fluid flow), whereas molecular 
diffusion in the interiors of dish-grown constructs supported 
only a low density of scattered cells. 
Sarcomeric a-actin, cardiac troponin I, and sarcomeric 
tropomyosin were present throughout the perfuscd construct 
volume (FIGS. 10, A and B). In contrast, dish-grown con-
structs exhibited spatially nonuniform cell distributions, with 
most cells expressing contractile proteins located within a 
100- to 300-µm-thick surface layer and only a small number 
of viable differentiated cells in the construct interior (FIGS. 
10, A and B). Constructs from both groups consisted mainly 
of mononucleated cells and exhibited a lack of well-estab-
lished structural alignment of the contractile proteins that was 
observed in native tissue. The central perfused regions of the 
constructs (5 mm diameterx 1.5 mm thick) consisted of tightly 
packed cells containing sarcomeric a-actin, cardiac troponin 
I, and sarcomeric iropomyosin, similar to neonatal rat ven-
tricles, and distinctly different from the tissue present in the 
centers of dish-grown constructs (5 mm diameterxl.5 mm 
thick), which contained only isolated and poorly differenti-
ated cells (FIG. 1013). 
Contractile function. The contractile function of engi-
neered cardiac constructs was evaluated by monitoring con-
tractile activity upon electrical stimulation at x10 magnifica-
tion using a microscope (Nikon Diaphot). Each construct was 
placed in a 100-mm petri dish containing 120 ml Tyrode 
solution (140 mM NaCl, 5.4 mM KCI, 0.33 mM NaH2PO41  
1.8 mM CaCl2, 1 mM MgCl2,  5 mM HEPES, and 5.5 MM 
D-glucose; pH 7.4) between two custom-made gold elec-
trodes connected to a cardiac stimulator (Nihon Kohden). The 
temperature was maintained at 37° C. using a heating tape 
(VWR) attached to the bottom of the petri dish. The stimuli 
(square pulses, 2-ms duration) were applied at a rate of 60 
beats/min starting at an amplitude of I V, which was gradually 
increased in 0.1-V increments until the excitation threshold 
(ET) was reached and the entire construct was observed to 
beat synchronously. 
The maximum capture rate (MCR) was defined as the 
maximum pacing frequency (in beats/min) for a synchronous 
stimulus response of the constructs. To measure MCR, the 
stimulation frequency was increased (from 60 to 600 beats/ 
min, in 20 beats/min increments) at a constant voltage (equal 
to either 150% or 200% of the ET). The construct response 
was measured at each frequency, and the frequency was 
increased until the contractions became asynchronous, 
irregular, or completely ceased. The maximum frequency for 
synchronous contractions was recorded as the MCR. The 
value of ET, which was different from one construct to 
another due to the differences in their structures, served as the 
baseline voltage for the measurement of MCR. 
Constructs cultured in perfused cartridges were compared 
with constructs cultured in mixed dishes and to neonatal rat 
ventricles (full thickness slices obtained by bisecting the left 
ventricle parallel to the base apex line). The effect of palmi- 
38 
toleic acid (PA), a gap junction blocker (4), was investigated 
by incubating constructs or slices of native ventricles in PA 
(8.3 mM in Tyrode solution) for 20 min at 37° C. and then 
determining ET and MCR as described above. To test whether 
5 the effect of PA was reversible, constructs were transferred to 
Tyrode solution and retested after an additional 20 min at 37° 
C. 
Spontaneous contractions were observed in some con- 
10 structs early in culture (dish-grown constructs 2-3 days after 
seeding) and ceased after —5 days of cultivation. At the end of 
cultivation (day 7), spontaneous contractions were not 
observed in either group of constructs. In response to electri-
cal stimulation (e.g., at 5 V and 60beats/min), constructs from 
15 both groups were reproducibly induced to contract synchro-
nously. However, in perfused constructs the contraction fre-
quency was constant, whereas in dish-grown 5 constructs the 
contraction frequency spontaneously increased every I to 2 
min and the contraction pattern appeared arrhythmic. The ET 
20 was significantly lower in perfused than dish-grown con-
structs, and all construct ETs were significantly higher than 
those measured for neonatal rat ventricles. There was no 
significant difference in the MCRs measured for the two 
groups at suprathreshold stimulus amplitudes (150% and 
25 200% ET; Table 2). 
TABLE 2 
Contractile Properties of Neonatal Ventricle, 7-Day Perfused 
30 	 Constructs, and 7-Day Dish-Grown Constructs 
Dish-grown 
Neonatal Rat 	 Perfused Construct Construct 
Ventricle 	 (7 days at 500 pm/s) (7 days at 25 rpm) 
Values are means +/— SE. Excitation threshold (ET) was measured at a stimulation frequency 
of 60 beats/min. The maximum capture rate (MCR) was measured at voltages equivalent to 
150% and 200% ET. Data were collected before the treatment with palmitoleic acid (before 
PA) and after the washout of palmitoleic acid (After PA) Constructs could not be induced to 
contract in the solution containing PA. P values were calculated by one0way ANOVA in 
conjunctionwith Tulcey's test for pair-wise multiple comparisons (N = 2-6). Differences 
55 were considered statistically significantifP <0.05. 
'Significant different between constructs and neonatal rat ventricles; 
bsignificant difference between perfused and dish-grown constructs; 
`significant difference before and after PA treatment 
60 	 Upon incubation with PA, a gap junction blocker, synchro- 
nous construct contractions could not be induced even at 9.9 
V. Contractile activity resumed after the washout of PA. The 
MCRs of perfused constructs and neonatal ventricles were 
similar to those recorded before PA treatment, suggesting that 
65 the effect of PA was completely reversible. However, the 
MCRs of dish-grown constructs failed to recover their base-
line levels after PA washout (Table 2). 
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Example 12 	 TABLE 3 
Electrical Stimulation of a Construct Seeded with 
Mesenchymal Stem Cells 
Unprocessed bone marrow was obtained from Clonetics 
(Santa Rosa, Calif.) from human donors without identifiers. 
Each 25-cm3 harvest was diluted in 100 ml of isolation 
medium (RPMI 1640 supplemented with 5% FBS, Gibco, 
Carlsbad, Calif.), and cells were separatedby density gradient 
centrifugation (Meinel, et al., 2003, Ann. Blomed. Eng., 32: 
112-122). 20 ml aliquots of bone marrow suspension were 
overlaid onto a Sodium Diatrizoate Poly-sucrose Gradients 
(1.077 g/cm3, Histopaque, Sigma, St. Louis, Mo.) and cen-
trifuged at 800 g for 30 min at room temperature. The cell 
layer was removed, washed in 10 ml isolation medium, and 
pelleted, and the red blood cells were lysed in 5 ml of Pure-
Gene Lysis solution (Sigma, St. Louis, Mo.). Cells were 
separated, resuspended in expansion medium (DMEM 
supplemented with 10% FBS and 1 ng/ml bFGF, Gibco, 
Carlsbad, Calif.) and seeded in T75 flasks at a density of 
5x104 cells/cm2 . The adherent cells were allowed to reach 
approximately 80% confluence (12-17 days for the first pas-
sage). Cells were trypsinized, plated and the second passage 
(P2) cells (80% confluence after 7 days) were used. 
The expression of surface antigens (CD44, CD31, CD34, 
CD71, and CD105) in P2 cells was determined by FACS 
analysis (Meinel, et al., 2003, Ann. Biomed. Eng., 32: 112-
122). Briefly, 50 ld aliquots of cell suspension (1x10' cells/ 
ml) were incubated with 2 ld of each of the following anti-
bodies: anti-CD44 conjugated with fluoresceine 
isothiocyanate (CD44-FITC), anti-CD31 conjugated with 
phycoerythrin (CD31-PE), anti CD34 conjugated with allo-
phycocyanine (CD34-APC), anti CD71-APC, and anti-
CD 105 with a secondary rat-anti mouse IgG-FITC (all from 
Pharmingen, San Diego, Calif.). Cells were suspended in 100 
ld of 2% formalin for FACS analysis. 
Collagen scaffolds were discs cored from sheets of 
Ultrafoam® collagen hemostat (Davol Inc., Cranston R. I.), a 
water-insoluble, partial HCl salt of purified bovine dermal 
(corium) collagen formed as a sponge with interconnected 
pores. For cultivation with electrical stimulation, MSCs were 
inoculated into collagen sponges (Ultrafoamrm, 6x8x1.5mm, 
5.106 cells per scaffold) using diluted Matrigel® (BD Bio-
sciences, Palo Alto, Calif.) (25 ld; 1:2 in culture medium) as 
a delivery vehicle. The constructs were placed in orbitally 
mixed dishes (25 rpm, one construct per well in 4 ml of 
culture medium) and stimulated in a spatially uniform elec-
trical field between two parallel electrodes using supra-
threshold square biphasic pulses (2ms duration, 1 Hz, 5 V). 
The conditions of stimulation were selected form the physi-
ological range for native heart muscle and designed to induce 
synchronous contractions of cultured constructs. The stimu-
lation was initiated after 12 hr to 1 day following scaffold 
seeding and applied for up to two weeks. 
Expanded MSC exhibited fibroblast-like morphology 
(FIG.11A). More than 90% of the cells expressed the surface 
antigen CD105/endoglin, a putative marker for mesenchymal 
stem cells (FIG. 11B). Negative expression of surface anti-
gens CD34 and CD31 suggested the absence of hematopoi-
etic progenitor cells and cells of endothelial origin. Most cells 
expressed CD71, a surface antigen commonly present in pro-
liferating cells, and CD44, the transmembrane hyaluronate 
receptor for osteopontin, ankyrin, and fibronectin (Table 3). 
FACS analysis of human mesenchymal stem cells isolated from bone 
marrow 
5 	 Passage 1 Passage 2 
Average Average 
Antigen Cell surface marker/identified cell type 	 expression expression 
CD34 	 Sialomucin/hematopoietic progenitors 	 — 	 — 
CD31 	 PECAM-1/endothelial cells 	 — 	 — 
10 CD71 	 Transferring receptor/proliferating cells 	 + 	 + 
CD44 	 Hyalmonate receptor/various cells 	 ++ 	 ++ 
Note: 
10,000 cells of passage 1 and passage 2 cells expanded from bone marrow have been 
measured, donated from two different donors. 
—, negative, defined as a fluorescence intensity <2% of the isotype control; 
15 +, fluorescence intensity 25-50% of the isotype control; 
++, fluorescence intensity 70 90% of the isotype control. 
To test the feasibility of directed differentiation of MSC 
towards cardiac cell lineages, MSC were inoculated into col- 
20 lagen sponges (6 mmx8 mmxl .5 mm patches, 5.10 6 cells per 
scaffold delivered using Matrigel(k) and cultured with the 
application of cardiac-like electrical stimulation. The con-
structs were placed in orbitally mixed dishes, cells were 
allowed to attach for 12 hrs, and electrical stimulation was 
25 initiated and applied continuously for up to 2 weeks (biphasic 
pulses, 2ms in duration, amplitude of 5V, constant frequency 
of 1 Hz); nonstimulated otherwise identical constructs served 
as controls. Like in native myocardium, electrical stimulation 
at a supra-threshold amplitude and constant frequency caused 
30 synchronous macroscopic contractions of cultured tissue 
constructs. After 4 days in culture, cells at the construct edges 
started to respond to pacing, presumably due to cell coupling. 
Immunostaining for cardiac troponin I and connexin 43 (gap 
junction protein) revealed a number of positive cells (FIGS. 
35 12A, B); immunostains for cartilage markers were negative. 
These initial data suggest that biophysical signals that are 
physiological in nature, magnitude and regime of application 
fort native myocardium can potentially direct the differentia-
tion of human MSC towards cardiac cell lineages. 
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What is claimed is: 
1. A method for producing a three-dimensional tissue-
engineered construct comprising: 
inoculating a three-dimensional substrate with a cell-gel 
45 	 suspension containing mammalian cells, thereby form- 
ing a cell-seeded construct; 
subjecting the cell-seeded construct to alternating flow per-
fusion through the construct immediately after the 
inoculating; 
50 	 supplying the cell-seeded construct with nutritive medium; 
cultivating the cell-seeded construct under conditions of 
direct medium perfusion, wherein the direct medium 
perfusion perfuses nutritive medium through the con-
struct and provides substantially uniform cell density 
55 throughout the cell-seeded construct at depths greater 
than about 100 microns up to about 5 mm, except in 
regions shielded from medium flow; 
and, during cultivation, submitting the cells within the 
cell-seeded construct to a biomimetic electrical stimu- 
60 lation, the cultivating of the cell-seeded construct and 
biomimetic electrical stimulation extending for a time 
period to form a three-dimensional cell structure exhib-
iting structural and functional characteristics of a native 
tissue. 
65 	 2. The method of claim 1, wherein the native tissue is one 
that contains electrically excitable cells and is subject to 
electrical stimulation in vivo. 
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3. The method of claim 2, wherein the native tissue is 	 27. The method of claim 1, wherein cultivating the cell- 
selected from the group consisting of cardiac muscle tissue, 	 seeded construct comprises employing conditions selected to 
striated skeletal muscle tissue, smooth muscle tissue, bone, 	 promote cell proliferation. 
vasculature, and nerve tissue. 	 28. The method of claim 1, wherein cultivating the cell- 
4. The method of claim 1, wherein cultivating the cell- 5 seeded construct comprises employing conditions selected to 
seeded construct comprises implanting the cell-seeded con- 	 promote cell differentiation. 
struct in vivo and placing the cell-seeded construct in electri- 	 29. The method of claim 1, wherein cultivating the cell- 
cal communication with a source of biomimetic electrical 	 seeded construct comprises employing conditions selected to 
stimulation. 	 allow the formation of a three-dimensional construct with a 
5. The method of claim 1, wherein the substrate is biocom-  io predetermined thickness. 
patible. 	 30. The method of claim 1, wherein cultivating the cell- 
6. The method of claim 1, wherein the substrate is biode- 	 seeded construct comprises employing conditions selected to 
gradable. 	 allow the formation of a three-dimensional construct, 
7. The method of claim 1, wherein the substrate is non- 	 wherein the mammalian cells are organized on the substrate 
biodegradable. 	 15 with a defined orientation. 
8. The method of claim 1, wherein the substrate has a dry 	 31. The method of claim 1, wherein the electrical stimula- 
thickness of at least 1.5 mm. 	 tion mimics the electrical stimulation received by a cardiac 
9. The method of claim 1, wherein the substrate comprises 	 muscle tissue in vivo. 
a polymer selected from the group consisting of a naturally- 	 32. The method of claim 31, wherein the electrical stimu- 
occurring polymer, a synthetic polymer, and any combination 20 lation promotes differentiation of progenitor cells into car-
thereof. 	 diac myocytes. 
10. The method of claim 1, wherein the mammalian cells 	 33. The method of claim 31, wherein the electrical stimu- 
comprise cells of one cell type. 	 lation promotes differentiation of stem cells into cardiac 
11. The method of claim 1, wherein the mammalian cells 	 myocytes. 
comprise cells of at least two different cell types. 	 25 	 34. The method of claim 1, wherein the electrical stimula- 
12. The method of claim 1, wherein the mammalian cells 	 tion mimics the electrical stimulation received by a native 
are neonatal cells. 	 tissue in vivo, the native tissue being selected from the group 
13. The method of claim 1, wherein the mammalian cells 	 consisting of striated skeletal muscle tissue, smooth muscle 
are adult or aged cells. 	 tissue, bone, vasculature, and nerve tissue. 
14. The method of claim 1, wherein the mammalian cells 30 	 35. The method of claim 1, further comprising stimulating 
are progenitor cells. 	 the cell-seeded construct chemically. 
15. The method of claim 14, wherein the progenitor cells 	 36. The method of claim 1, further comprising treating the 
are derived from a ti ssue selected from the group consisting of 	 three-dimensional tissue-engineered construct with at least 
bone marrow, fat and umbilical cord. 	 one biologically active agent. 
16. The method of claim 1, wherein the mammalian cells 35 	 37. The method of claim 36, wherein the biologically 
are adult stem cells. 	 active agent is selected from the group consisting of growth 
17. The method of claim 1, wherein the mammalian cells 	 factors, adhesion factors, soluble extracellular matrix pro- 
are embryonic stem cells. 	 teins, antibiotics, agents that enhance vascularization, agents 
18. The method of claim 1, wherein the mammalian cells 	 that enhance cell differentiation, agents that enhance tissue 
are mesenchymal stem cells (MSC). 	 4o differentiation, agents that inhibit fibrosis, agents that inhibit 
19. The method of claim 1, wherein the mammalian cells 	 tumorigenesis, agents that enhance cell proliferation, agents 
are genetically transformed cells. 	 that inhibit cell proliferation, agents that inhibit scaffold deg- 
20. The method of claim 1, wherein the mammalian cells 	 radation, agents that enhance scaffold degradation, agents 
are human cells. 	 that improve histocompatibility, and agents that enhance 
21. The method of claim 1, further comprising: harvesting 45 hemocompatibility. 
mammalian cells from an individual; and cultivating the har- 	 38. The method of claim 1, further comprising storing the 
vested cells in vitro before contacting the substrate. 	 three-dimensional tissue-engineered construct. 
22. The method of claim 21, wherein the individual is 	 39. The method of claim 1 further comprising: 
intended to be the recipient of the construct. 	 capturing a tissue response with the biomimetic electrical 
23. The method of claim 1, wherein the mammalian cells 50 	 stimulation so as to achieve a stable tissue response. 
are cells from an established cell line. 	 40. The method of claim 1, wherein the substrate comprises 
24. The method of claim 1, wherein the construct is a 	 a collagen sponge. 
cardiac muscle construct, and wherein the mammalian cells 	 41. The method of claim 1, wherein the substrate comprises 
are selected from the group consisting of cardiomyocytes, 	 a water-insoluble, partial HCl salt of purified bovine dermal 
endocardial cells, cardiac adrenergic cells, cardiac fibro-  55 collagen formed as a sponge with interconnected pores. 
blasts, vascular endothelial cells, smooth muscle cells, car- 	 42. The method of claim 1, wherein the substrate comprises 
diac progenitor cells, adult stem cells, embryonic stem cells, 	 a naturally-occurring polymer selected from the following 
mesenchymal stem cells and any combination thereof. 	 group: starch, dextran, cellulose, and hyaluronic acid. 
25. The method of claim 24, wherein the mammalian cells 	 43. The method of claim 42, wherein the starch, dextran, or 
are selected from the group consisting of cardiomyocytes, 60 cellulose has been modified physically or chemically to affect 
endocardial cells, cardiac adrenergic cells, cardiac fibro- 	 one or more of its properties selected from the following 
blasts, vascular endothelial cells, smooth muscle cells, car- 	 group: characteristics in the hydrated state, solubility, half- 
diac progenitor cells, and any combination thereof. 	 life in vivo. 
26. The method of claim 1, wherein cultivating the cell- 	 44. The method of claim 1, wherein the substrate comprises 
seeded construct comprises employing conditions selected to 65 collagen or gelatin. 
promote cellular production of extracellular matrix compo- 	 45. The method of claim 1, wherein the substrate comprises 
nents. 	 a polymer selected from the following group: polyanhy- 
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drides, polyorthoesters, polyphosphazenes, polycaprolac-
tones, polyamides, polyurethanes, polyesteramides, poly-
dioxanones, polyacetals, polyketals, polycarbonates, 
polyorthocarbonates, polyhydroxybutyrates, polyhydroxy-
valerates, polyalkylene oxalates, polyalkylene succinates, 
poly(malic acid), poly(amino acids), poly(methyl vinyl 
44 
ether), poly(maleic anhydride), chitin, chitosan, and copoly-
mers, terpolymers, or higher poly-monomer polymers 
thereof, or combinations or mixtures thereof. 
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